h275,https://www.ema.europa.eu/documents/scientific-discussion/litak-epar-scientific-discussion_en.pdf
h274,https://www.ema.europa.eu/documents/scientific-discussion/velcade-epar-scientific-discussion_en.pdf
h273,https://www.ema.europa.eu/documents/scientific-discussion/lysodren-epar-scientific-discussion_en.pdf
h277,https://www.ema.europa.eu/documents/scientific-discussion/tachosil-epar-scientific-discussion_en.pdf
h282,https://www.ema.europa.eu/documents/scientific-discussion/telzir-epar-scientific-discussion_en.pdf
h278,https://www.ema.europa.eu/documents/scientific-discussion/levemir-epar-scientific-discussion_en.pdf
h091,https://www.ema.europa.eu/documents/scientific-discussion/kinzalmono-epar-scientific-discussion_en.pdf
h281,https://www.ema.europa.eu/documents/scientific-discussion/erbitux-epar-scientific-discussion_en.pdf
h276,https://www.ema.europa.eu/documents/scientific-discussion/abilify-epar-scientific-discussion_en.pdf
h290,https://www.ema.europa.eu/documents/scientific-discussion/alimta-epar-scientific-discussion_en.pdf
h298,https://www.ema.europa.eu/documents/scientific-discussion/kivexa-epar-scientific-discussion_en.pdf
h295,https://www.ema.europa.eu/documents/scientific-discussion/xagrid-epar-scientific-discussion_en.pdf
h294,https://www.ema.europa.eu/documents/scientific-discussion/emselex-epar-scientific-discussion_en.pdf
h296,https://www.ema.europa.eu/documents/scientific-discussion/cymbalta-epar-scientific-discussion_en.pdf
h302,https://www.ema.europa.eu/documents/scientific-discussion/prialt-epar-scientific-discussion_en.pdf
h299,https://www.ema.europa.eu/documents/scientific-discussion/fendrix-epar-scientific-discussion_en.pdf
h303,https://www.ema.europa.eu/documents/scientific-discussion/orfadin-epar-scientific-discussion_en.pdf
h300,https://www.ema.europa.eu/documents/scientific-discussion/avastin-epar-scientific-discussion_en.pdf
h285,https://www.ema.europa.eu/documents/scientific-discussion/apidra-epar-scientific-discussion_en.pdf
h286,https://www.ema.europa.eu/documents/scientific-discussion/wilzin-epar-scientific-discussion_en.pdf
h292,https://www.ema.europa.eu/documents/scientific-discussion/mimpara-epar-scientific-discussion_en.pdf
h306,https://www.ema.europa.eu/documents/scientific-discussion/aloxi-epar-scientific-discussion_en.pdf
h305,https://www.ema.europa.eu/documents/scientific-discussion/truvada-epar-scientific-discussion_en.pdf
h304,https://www.ema.europa.eu/documents/scientific-discussion/azilect-epar-scientific-discussion_en.pdf
h310,https://www.ema.europa.eu/documents/scientific-discussion/fosavance-epar-scientific-discussion_en.pdf
h312,https://www.ema.europa.eu/documents/scientific-discussion/xyrem-epar-scientific-discussion_en.pdf
h315,https://www.ema.europa.eu/documents/scientific-discussion/aptivus-epar-scientific-discussion_en.pdf
h308,https://www.ema.europa.eu/documents/scientific-discussion/aclasta-epar-scientific-discussion_en.pdf
h316,https://www.ema.europa.eu/documents/scientific-discussion/procoralan-epar-scientific-discussion_en.pdf
h307,https://www.ema.europa.eu/documents/scientific-discussion/zonegran-epar-scientific-discussion_en.pdf
h322,https://www.ema.europa.eu/documents/scientific-discussion/yttriga-epar-scientific-discussion_en.pdf
h311,https://www.ema.europa.eu/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf
h328,https://www.ema.europa.eu/documents/scientific-discussion/cubicin-epar-scientific-discussion_en.pdf
h323,https://www.ema.europa.eu/documents/scientific-discussion/proquad-epar-scientific-discussion_en.pdf
h317,https://www.ema.europa.eu/documents/scientific-discussion/corlentor-epar-scientific-discussion_en.pdf
h320,https://www.ema.europa.eu/documents/scientific-discussion/noxafil-epar-scientific-discussion_en.pdf
h319,https://www.ema.europa.eu/documents/scientific-discussion/xolair-epar-scientific-discussion_en.pdf
h324,https://www.ema.europa.eu/documents/scientific-discussion/naglazyme-epar-scientific-discussion_en.pdf
h318,https://www.ema.europa.eu/documents/scientific-discussion/revatio-epar-scientific-discussion_en.pdf
h331,https://www.ema.europa.eu/documents/scientific-discussion/neupro-epar-scientific-discussion_en.pdf
h330,https://www.ema.europa.eu/documents/scientific-discussion/rotarix-epar-scientific-discussion_en.pdf
h332,https://www.ema.europa.eu/documents/scientific-discussion/omnitrope-epar-scientific-discussion_en.pdf
h333,https://www.ema.europa.eu/documents/scientific-discussion/myozyme-epar-scientific-discussion_en.pdf
h329,https://www.ema.europa.eu/documents/scientific-discussion/kiovig-epar-scientific-discussion_en.pdf
h338,https://www.ema.europa.eu/documents/scientific-discussion/duotrav-epar-scientific-discussion_en.pdf
h334,https://www.ema.europa.eu/documents/scientific-discussion/evoltra-epar-scientific-discussion_en.pdf
h336,https://www.ema.europa.eu/documents/scientific-discussion/tygacil-epar-scientific-discussion_en.pdf
h340,https://www.ema.europa.eu/documents/scientific-discussion/ganfort-epar-scientific-discussion_en.pdf
h337,https://www.ema.europa.eu/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf
h341,https://www.ema.europa.eu/documents/scientific-discussion/zostavax-epar-scientific-discussion_en.pdf
h347,https://www.ema.europa.eu/documents/scientific-discussion/sutent-epar-scientific-discussion_en.pdf
h346,https://www.ema.europa.eu/documents/scientific-discussion/tysabri-epar-scientific-discussion_en.pdf
h350,https://www.ema.europa.eu/documents/scientific-discussion/savene-epar-scientific-discussion_en.pdf
h348,https://www.ema.europa.eu/documents/scientific-discussion/rotateq-epar-scientific-discussion_en.pdf
h279,https://www.ema.europa.eu/documents/scientific-discussion/lyrica-epar-scientific-discussion_en.pdf
h284,https://www.ema.europa.eu/documents/scientific-discussion/pedea-epar-scientific-discussion_en.pdf
h361,https://www.ema.europa.eu/documents/scientific-discussion/luminity-epar-scientific-discussion_en.pdf
h359,https://www.ema.europa.eu/documents/scientific-discussion/suboxone-epar-scientific-discussion_en.pdf
h360,https://www.ema.europa.eu/documents/scientific-discussion/champix-epar-scientific-discussion_en.pdf
h280,https://www.ema.europa.eu/documents/scientific-discussion/yentreve-epar-scientific-discussion_en.pdf
h354,https://www.ema.europa.eu/documents/scientific-discussion/competact-epar-scientific-discussion_en.pdf
h342,https://www.ema.europa.eu/documents/scientific-discussion/nexavar-epar-scientific-discussion_en.pdf
h363,https://www.ema.europa.eu/documents/scientific-discussion/sprycel-epar-scientific-discussion_en.pdf
h362,https://www.ema.europa.eu/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf
h365,https://www.ema.europa.eu/documents/scientific-discussion/elaprase-epar-scientific-discussion_en.pdf
h366,https://www.ema.europa.eu/documents/scientific-discussion/tandemact-epar-scientific-discussion_en.pdf
h378,https://www.ema.europa.eu/documents/scientific-discussion/inovelon-epar-scientific-discussion_en.pdf
h367,https://www.ema.europa.eu/documents/scientific-discussion/diacomit-epar-scientific-discussion_en.pdf
h376,https://www.ema.europa.eu/documents/scientific-discussion/irbesartan-winthrop-epar-scientific-discussion_en.pdf
h372,https://www.ema.europa.eu/documents/scientific-discussion/copalia-epar-scientific-discussion_en.pdf
h379,https://www.ema.europa.eu/documents/scientific-discussion/cystadane-epar-scientific-discussion_en.pdf
h370,https://www.ema.europa.eu/documents/procedural-steps/exforge-epar-procedural-steps-taken-authorisation_en.pdf
h371,https://www.ema.europa.eu/documents/scientific-discussion/dafiro-epar-scientific-discussion_en.pdf
h377,https://www.ema.europa.eu/documents/scientific-discussion/irbesartan-hydrochlorothiazide-winthrop-epar-scientific-discussion_en.pdf
h374,https://www.ema.europa.eu/documents/scientific-discussion/lucentis-epar-scientific-discussion_en.pdf
h387,https://www.ema.europa.eu/documents/scientific-discussion/advagraf-epar-scientific-discussion_en.pdf
h386,https://www.ema.europa.eu/documents/scientific-discussion/toviaz-epar-scientific-discussion_en.pdf
h382,https://www.ema.europa.eu/documents/scientific-discussion/xelevia-epar-scientific-discussion_en.pdf
h383,https://www.ema.europa.eu/documents/scientific-discussion/januvia-epar-scientific-discussion_en.pdf
h392,https://www.ema.europa.eu/documents/scientific-discussion/circadin-epar-scientific-discussion_en.pdf
h380,https://www.ema.europa.eu/documents/scientific-discussion/prezista-epar-scientific-discussion_en.pdf
h399,https://www.ema.europa.eu/documents/scientific-discussion/aerinaze-epar-scientific-discussion_en.pdf
h400,https://www.ema.europa.eu/documents/procedural-steps/mircera-epar-procedural-steps-taken-authorisation_en.pdf
h389,https://www.ema.europa.eu/documents/scientific-discussion/orencia-epar-scientific-discussion_en.pdf
h395,https://www.ema.europa.eu/documents/scientific-discussion/invega-epar-scientific-discussion_en.pdf
h393,https://www.ema.europa.eu/documents/scientific-discussion/soliris-epar-scientific-discussion_en.pdf
h391,https://www.ema.europa.eu/documents/scientific-discussion/revlimid-epar-scientific-discussion_en.pdf
h403,https://www.ema.europa.eu/documents/scientific-discussion/atriance-epar-scientific-discussion_en.pdf
h402,https://www.ema.europa.eu/documents/scientific-discussion/increlex-epar-scientific-discussion_en.pdf
h404,https://www.ema.europa.eu/documents/procedural-steps/flebogammadif-epar-procedural-steps-taken-authorisation_en.pdf
h356,https://www.ema.europa.eu/documents/scientific-discussion/exjade-epar-scientific-discussion_en.pdf
h410,https://www.ema.europa.eu/documents/scientific-discussion/binocrit-epar-scientific-discussion_en.pdf
h401,https://www.ema.europa.eu/documents/scientific-discussion/alli-epar-scientific-discussion_en.pdf
h412,https://www.ema.europa.eu/documents/scientific-discussion/abseamed-epar-scientific-discussion_en.pdf
h357,https://www.ema.europa.eu/documents/scientific-discussion/gardasil-epar-scientific-discussion_en.pdf
h413,https://www.ema.europa.eu/documents/scientific-discussion/gliolan-epar-scientific-discussion_en.pdf
h405,https://www.ema.europa.eu/documents/scientific-discussion/rasilez-epar-scientific-discussion_en.pdf
h414,https://www.ema.europa.eu/documents/scientific-discussion/galvus-epar-scientific-discussion_en.pdf
h397,https://www.ema.europa.eu/documents/scientific-discussion/siklos-epar-scientific-discussion_en.pdf
h415,https://www.ema.europa.eu/documents/scientific-discussion/zalasta-epar-scientific-discussion_en.pdf
h364,https://www.ema.europa.eu/documents/scientific-discussion/adrovance-epar-scientific-discussion_en.pdf
h416,https://www.ema.europa.eu/documents/scientific-discussion/ecalta-epar-scientific-discussion_en.pdf
h418,https://www.ema.europa.eu/documents/scientific-discussion/celsentri-epar-scientific-discussion_en.pdf
h411,https://www.ema.europa.eu/documents/scientific-discussion/epoetin-alfa-hexal-epar-scientific-discussion_en.pdf
h419,https://www.ema.europa.eu/documents/scientific-discussion/cervarix-epar-scientific-discussion_en.pdf
h427,https://www.ema.europa.eu/documents/scientific-discussion/olanzapine-teva-epar-scientific-discussion_en.pdf
h422,https://www.ema.europa.eu/documents/scientific-discussion/tasigna-epar-scientific-discussion_en.pdf
h425,https://www.ema.europa.eu/documents/scientific-discussion/eucreas-epar-scientific-discussion_en.pdf
h428,https://www.ema.europa.eu/documents/assessment-report/abraxane-epar-public-assessment-report_en.pdf
h424,https://www.ema.europa.eu/documents/scientific-discussion/torisel-epar-scientific-discussion_en.pdf
h431,https://www.ema.europa.eu/documents/scientific-discussion/retacrit-epar-scientific-discussion_en.pdf
h417,https://www.ema.europa.eu/documents/scientific-discussion/yondelis-epar-scientific-discussion_en.pdf
h433,https://www.ema.europa.eu/documents/scientific-discussion/nevanac-epar-scientific-discussion_en.pdf
h432,https://www.ema.europa.eu/documents/scientific-discussion/silapo-epar-scientific-discussion_en.pdf
h423,https://www.ema.europa.eu/documents/scientific-discussion/vectibix-epar-scientific-discussion_en.pdf
h439,https://www.ema.europa.eu/documents/assessment-report/mycophenolate-mofetil-teva-epar-public-assessment-report_en.pdf
h396,https://www.ema.europa.eu/documents/scientific-discussion/pergoveris-epar-scientific-discussion_en.pdf
h438,https://www.ema.europa.eu/documents/assessment-report/myfenax-epar-public-assessment-report_en.pdf
h441,https://www.ema.europa.eu/documents/scientific-discussion/effentora-epar-scientific-discussion_en.pdf
h440,https://www.ema.europa.eu/documents/assessment-report/tyverb-epar-public-assessment-report_en.pdf
h446,https://www.ema.europa.eu/documents/assessment-report/privigen-epar-public-assessment-report_en.pdf
h447,https://www.ema.europa.eu/documents/assessment-report/adenuric-epar-public-assessment-report_en.pdf
h003,https://www.ema.europa.eu/documents/scientific-discussion/betaferon-epar-scientific-discussion_en.pdf
h005,https://www.ema.europa.eu/documents/scientific-discussion/cellcept-epar-scientific-discussion_en.pdf
h004,https://www.ema.europa.eu/documents/scientific-discussion/fareston-epar-scientific-discussion_en.pdf
h442,https://www.ema.europa.eu/documents/assessment-report/pradaxa-epar-public-assessment-report_en.pdf
h006,https://www.ema.europa.eu/documents/scientific-discussion/novoseven-epar-scientific-discussion_en.pdf
h008,https://www.ema.europa.eu/documents/scientific-discussion/puregon-epar-scientific-discussion_en.pdf
h007,https://www.ema.europa.eu/documents/scientific-discussion/humalog-epar-scientific-discussion_en.pdf
h012,https://www.ema.europa.eu/documents/scientific-discussion/bondronat-epar-scientific-discussion_en.pdf
h033,https://www.ema.europa.eu/documents/scientific-discussion/avonex-epar-scientific-discussion_en.pdf
h018,https://www.ema.europa.eu/documents/scientific-discussion/rapilysin-epar-scientific-discussion_en.pdf
h010,https://www.ema.europa.eu/documents/scientific-discussion/rilutek-epar-scientific-discussion_en.pdf
h002,https://www.ema.europa.eu/documents/scientific-discussion/taxotere-epar-scientific-discussion_en.pdf
h020,https://www.ema.europa.eu/documents/scientific-discussion/twinrix-adult-epar-scientific-discussion_en.pdf
h031,https://www.ema.europa.eu/documents/scientific-discussion/neorecormon-epar-scientific-discussion_en.pdf
h027,https://www.ema.europa.eu/documents/scientific-discussion/hycamtin-epar-scientific-discussion_en.pdf
h015,https://www.ema.europa.eu/documents/scientific-discussion/epivir-epar-scientific-discussion_en.pdf
h029,https://www.ema.europa.eu/documents/scientific-discussion/twinrix-paediatric-epar-scientific-discussion_en.pdf
h044,https://www.ema.europa.eu/documents/scientific-discussion/tasmar-epar-scientific-discussion_en.pdf
h039,https://www.ema.europa.eu/documents/scientific-discussion/cystagon-epar-scientific-discussion_en.pdf
h045,https://www.ema.europa.eu/documents/scientific-discussion/helicobacter-test-infai-epar-scientific-discussion_en.pdf
h047,https://www.ema.europa.eu/documents/scientific-discussion/benefix-epar-scientific-discussion_en.pdf
h022,https://www.ema.europa.eu/documents/scientific-discussion/zyprexa-epar-scientific-discussion_en.pdf
h016,https://www.ema.europa.eu/documents/scientific-discussion/norvir-epar-scientific-discussion_en.pdf
h046,https://www.ema.europa.eu/documents/scientific-discussion/aprovel-epar-scientific-discussion_en.pdf
h051,https://www.ema.europa.eu/documents/scientific-discussion/mirapexin-epar-scientific-discussion_en.pdf
h053,https://www.ema.europa.eu/documents/scientific-discussion/cerezyme-epar-scientific-discussion_en.pdf
h420,https://www.ema.europa.eu/documents/procedural-steps/cyanokit-epar-procedural-steps-taken-authorisation_en.pdf
h050,https://www.ema.europa.eu/documents/scientific-discussion/sifrol-epar-scientific-discussion_en.pdf
h055,https://www.ema.europa.eu/documents/scientific-discussion/viramune-epar-scientific-discussion_en.pdf
h065,https://www.ema.europa.eu/documents/procedural-steps/optison-epar-procedural-steps-taken-authorisation_en.pdf
h066,https://www.ema.europa.eu/documents/scientific-discussion/exelon-epar-scientific-discussion_en.pdf
h058,https://www.ema.europa.eu/documents/scientific-discussion/combivir-epar-scientific-discussion_en.pdf
h067,https://www.ema.europa.eu/documents/scientific-discussion/mabthera-epar-scientific-discussion_en.pdf
h064,https://www.ema.europa.eu/documents/scientific-discussion/pylobactell-epar-scientific-discussion_en.pdf
h057,https://www.ema.europa.eu/documents/scientific-discussion/quadramet-epar-scientific-discussion_en.pdf
h063,https://www.ema.europa.eu/documents/scientific-discussion/rebif-epar-scientific-discussion_en.pdf
h343,https://www.ema.europa.eu/documents/scientific-discussion/baraclude-epar-scientific-discussion_en.pdf
h073,https://www.ema.europa.eu/documents/scientific-discussion/evista-epar-scientific-discussion_en.pdf
h436,https://www.ema.europa.eu/documents/scientific-discussion/isentress-epar-scientific-discussion_en.pdf
h069,https://www.ema.europa.eu/documents/scientific-discussion/plavix-epar-scientific-discussion_en.pdf
h076,https://www.ema.europa.eu/documents/scientific-discussion/novonorm-epar-scientific-discussion_en.pdf
h074,https://www.ema.europa.eu/documents/scientific-discussion/optruma-epar-scientific-discussion_en.pdf
h071,https://www.ema.europa.eu/documents/scientific-discussion/xenical-epar-scientific-discussion_en.pdf
h080,https://www.ema.europa.eu/documents/scientific-discussion/aldara-epar-scientific-discussion_en.pdf
h081,https://www.ema.europa.eu/documents/scientific-discussion/comtan-epar-scientific-discussion_en.pdf
h084,https://www.ema.europa.eu/documents/scientific-discussion/simulect-epar-scientific-discussion_en.pdf
h082,https://www.ema.europa.eu/documents/scientific-discussion/comtess-epar-scientific-discussion_en.pdf
h077,https://www.ema.europa.eu/documents/scientific-discussion/viagra-epar-scientific-discussion_en.pdf
h030,https://www.ema.europa.eu/documents/scientific-discussion/insuman-epar-scientific-discussion_en.pdf
h095,https://www.ema.europa.eu/documents/scientific-discussion/emadine-epar-scientific-discussion_en.pdf
h089,https://www.ema.europa.eu/documents/scientific-discussion/pritor-epar-scientific-discussion_en.pdf
h096,https://www.ema.europa.eu/documents/scientific-discussion/temodal-epar-scientific-discussion_en.pdf
h090,https://www.ema.europa.eu/documents/scientific-discussion/micardis-epar-scientific-discussion_en.pdf
h097,https://www.ema.europa.eu/documents/scientific-discussion/beromun-epar-scientific-discussion_en-0.pdf
h070,https://www.ema.europa.eu/documents/scientific-discussion/iscover-epar-scientific-discussion_en.pdf
h103,https://www.ema.europa.eu/documents/scientific-discussion/refacto-af-epar-scientific-discussion_en.pdf
h100,https://www.ema.europa.eu/documents/scientific-discussion/cetrotide-epar-scientific-discussion_en.pdf
h108,https://www.ema.europa.eu/documents/scientific-discussion/ferriprox-epar-scientific-discussion_en.pdf
h111,https://www.ema.europa.eu/documents/scientific-discussion/stocrin-epar-scientific-discussion_en.pdf
h107,https://www.ema.europa.eu/documents/scientific-discussion/rebetol-epar-scientific-discussion_en.pdf
h109,https://www.ema.europa.eu/documents/scientific-discussion/integrilin-epar-scientific-discussion_en.pdf
h112,https://www.ema.europa.eu/documents/scientific-discussion/ziagen-epar-scientific-discussion_en.pdf
h119,https://www.ema.europa.eu/documents/scientific-discussion/novorapid-epar-scientific-discussion_en.pdf
h026,https://www.ema.europa.eu/documents/scientific-discussion/invirase-epar-scientific-discussion_en.pdf
h049,https://www.ema.europa.eu/documents/scientific-discussion/karvea-epar-scientific-discussion_en.pdf
h114,https://www.ema.europa.eu/documents/scientific-discussion/zeffix-epar-scientific-discussion_en.pdf
h110,https://www.ema.europa.eu/documents/scientific-discussion/sustiva-epar-scientific-discussion_en.pdf
h118,https://www.ema.europa.eu/documents/scientific-discussion/arava-epar-scientific-discussion_en.pdf
h434,https://www.ema.europa.eu/documents/scientific-discussion/avamys-epar-scientific-discussion_en.pdf
h117,https://www.ema.europa.eu/documents/scientific-discussion/synagis-epar-scientific-discussion_en.pdf
h116,https://www.ema.europa.eu/documents/scientific-discussion/remicade-epar-scientific-discussion_en.pdf
h120,https://www.ema.europa.eu/documents/scientific-discussion/ammonaps-epar-scientific-discussion_en.pdf
h122,https://www.ema.europa.eu/documents/scientific-discussion/thyrogen-epar-scientific-discussion_en.pdf
h130,https://www.ema.europa.eu/documents/scientific-discussion/orgalutran-epar-scientific-discussion_en.pdf
h129,https://www.ema.europa.eu/documents/scientific-discussion/azopt-epar-scientific-discussion_en.pdf
h125,https://www.ema.europa.eu/documents/scientific-discussion/zyprexa-velotab-epar-scientific-discussion_en.pdf
h134,https://www.ema.europa.eu/documents/scientific-discussion/lantus-epar-scientific-discussion_en.pdf
h135,https://www.ema.europa.eu/documents/scientific-discussion/datscan-epar-scientific-discussion_en.pdf
h126,https://www.ema.europa.eu/documents/scientific-discussion/enbrel-epar-scientific-discussion_en.pdf
h124,https://www.ema.europa.eu/documents/scientific-discussion/tractocile-epar-scientific-discussion_en.pdf
h142,https://www.ema.europa.eu/documents/scientific-discussion/novomix-epar-scientific-discussion_en.pdf
h149,https://www.ema.europa.eu/documents/scientific-discussion/panretin-epar-scientific-discussion_en.pdf
h140,https://www.ema.europa.eu/documents/scientific-discussion/visudyne-epar-scientific-discussion_en.pdf
h143,https://www.ema.europa.eu/documents/scientific-discussion/kogenate-bayer-epar-scientific-discussion_en.pdf
h145,https://www.ema.europa.eu/documents/scientific-discussion/herceptin-epar-scientific-discussion_en.pdf
h092,https://www.ema.europa.eu/documents/scientific-discussion/prometax-epar-scientific-discussion_en.pdf
h152,https://www.ema.europa.eu/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf
h086,https://www.ema.europa.eu/documents/scientific-discussion/coaprovel-epar-scientific-discussion_en.pdf
h162,https://www.ema.europa.eu/documents/scientific-discussion/prandin-epar-scientific-discussion_en.pdf
h146,https://www.ema.europa.eu/documents/scientific-discussion/keppra-epar-scientific-discussion_en.pdf
h157,https://www.ema.europa.eu/documents/scientific-discussion/azomyr-epar-scientific-discussion_en.pdf
h156,https://www.ema.europa.eu/documents/scientific-discussion/trizivir-epar-scientific-discussion_en.pdf
h160,https://www.ema.europa.eu/documents/scientific-discussion/aerius-epar-scientific-discussion_en.pdf
h150,https://www.ema.europa.eu/documents/scientific-discussion/actos-epar-scientific-discussion_en.pdf
h161,https://www.ema.europa.eu/documents/scientific-discussion/neoclarityn-epar-scientific-discussion_en.pdf
h165,https://www.ema.europa.eu/documents/scientific-discussion/ovitrelle-epar-scientific-discussion_en.pdf
h155,https://www.ema.europa.eu/documents/assessment-report/luveris-epar-public-assessment-report_en.pdf
h169,https://www.ema.europa.eu/documents/scientific-discussion/metalyse-epar-scientific-discussion_en.pdf
h164,https://www.ema.europa.eu/documents/scientific-discussion/nutropinaq-epar-scientific-discussion_en.pdf
h170,https://www.ema.europa.eu/documents/scientific-discussion/fasturtec-epar-scientific-discussion_en.pdf
h173,https://www.ema.europa.eu/documents/scientific-discussion/vaniqa-epar-scientific-discussion_en.pdf
h172,https://www.ema.europa.eu/documents/scientific-discussion/kaletra-epar-scientific-discussion_en.pdf
h163,https://www.ema.europa.eu/documents/scientific-discussion/xeloda-epar-scientific-discussion_en.pdf
h190,https://www.ema.europa.eu/documents/scientific-discussion/ceprotin-epar-scientific-discussion_en.pdf
h177,https://www.ema.europa.eu/documents/scientific-discussion/sonovue-epar-scientific-discussion_en.pdf
h176,https://www.ema.europa.eu/documents/scientific-discussion/zometa-epar-scientific-discussion_en.pdf
h183,https://www.ema.europa.eu/documents/scientific-discussion/hbvaxpro-epar-scientific-discussion_en.pdf
h188,https://www.ema.europa.eu/documents/scientific-discussion/fabrazyme-epar-scientific-discussion_en.pdf
h189,https://www.ema.europa.eu/documents/scientific-discussion/replagal-epar-scientific-discussion_en.pdf
h194,https://www.ema.europa.eu/documents/scientific-discussion/inomax-epar-scientific-discussion_en.pdf
h185,https://www.ema.europa.eu/documents/scientific-discussion/aranesp-epar-scientific-discussion_en.pdf
h196,https://www.ema.europa.eu/documents/scientific-discussion/cancidas-epar-scientific-discussion_en.pdf
h195,https://www.ema.europa.eu/documents/scientific-discussion/liprolog-epar-scientific-discussion_en.pdf
h198,https://www.ema.europa.eu/documents/scientific-discussion/glivec-epar-scientific-discussion_en.pdf
h201,https://www.ema.europa.eu/documents/scientific-discussion/protopic-epar-scientific-discussion_en.pdf
h199,https://www.ema.europa.eu/documents/scientific-discussion/travatan-epar-scientific-discussion_en.pdf
h197,https://www.ema.europa.eu/documents/scientific-discussion/foscan-epar-scientific-discussion_en.pdf
h209,https://www.ema.europa.eu/documents/scientific-discussion/dynastat-epar-scientific-discussion_en.pdf
h206,https://www.ema.europa.eu/documents/scientific-discussion/arixtra-epar-scientific-discussion_en.pdf
h203,https://www.ema.europa.eu/documents/scientific-discussion/kineret-epar-scientific-discussion_en.pdf
h205,https://www.ema.europa.eu/documents/scientific-discussion/lumigan-epar-scientific-discussion_en.pdf
h212,https://www.ema.europa.eu/documents/scientific-discussion/vfend-epar-scientific-discussion_en.pdf
h217,https://www.ema.europa.eu/documents/scientific-discussion/opatanol-epar-scientific-discussion_en.pdf
h216,https://www.ema.europa.eu/documents/scientific-discussion/invanz-epar-scientific-discussion_en.pdf
h215,https://www.ema.europa.eu/documents/scientific-discussion/pritorplus-epar-scientific-discussion_en.pdf
h166,https://www.ema.europa.eu/documents/scientific-discussion/neurobloc-epar-scientific-discussion_en.pdf
h171,https://www.ema.europa.eu/documents/scientific-discussion/rapamune-epar-scientific-discussion_en.pdf
h213,https://www.ema.europa.eu/documents/scientific-discussion/micardisplus-epar-scientific-discussion_en.pdf
h219,https://www.ema.europa.eu/documents/scientific-discussion/ebixa-epar-scientific-discussion_en.pdf
h218,https://www.ema.europa.eu/documents/scientific-discussion/axura-epar-scientific-discussion_en.pdf
h223,https://www.ema.europa.eu/documents/scientific-discussion/evra-epar-scientific-discussion_en.pdf
h224,https://www.ema.europa.eu/documents/scientific-discussion/ambirix-epar-scientific-discussion_en.pdf
h221,https://www.ema.europa.eu/documents/scientific-discussion/pegasys-epar-scientific-discussion_en.pdf
h230,https://www.ema.europa.eu/documents/scientific-discussion/actrapid-epar-scientific-discussion_en.pdf
h220,https://www.ema.europa.eu/documents/scientific-discussion/tracleer-epar-scientific-discussion_en.pdf
h226,https://www.ema.europa.eu/documents/scientific-discussion/inductos-epar-scientific-discussion_en.pdf
h222,https://www.ema.europa.eu/documents/scientific-discussion/tamiflu-epar-scientific-discussion_en.pdf
h234,https://www.ema.europa.eu/documents/scientific-discussion/protaphane-epar-scientific-discussion_en.pdf
h233,https://www.ema.europa.eu/documents/procedural-steps/insulatard-epar-procedural-steps-taken-authorisation_en.pdf
h231,https://www.ema.europa.eu/documents/scientific-discussion/mixtard-epar-scientific-discussion_en.pdf
h227,https://www.ema.europa.eu/documents/scientific-discussion/neulasta-epar-scientific-discussion_en.pdf
h229,https://www.ema.europa.eu/documents/scientific-discussion/actraphane-epar-scientific-discussion_en.pdf
h238,https://www.ema.europa.eu/documents/scientific-discussion/zavesca-epar-scientific-discussion_en.pdf
h237,https://www.ema.europa.eu/documents/scientific-discussion/cialis-epar-scientific-discussion_en.pdf
h246,https://www.ema.europa.eu/documents/scientific-discussion/carbaglu-epar-scientific-discussion_en.pdf
h249,https://www.ema.europa.eu/documents/scientific-discussion/vivanza-epar-scientific-discussion_en.pdf
h200,https://www.ema.europa.eu/documents/scientific-discussion/viread-epar-scientific-discussion_en.pdf
h247,https://www.ema.europa.eu/documents/scientific-discussion/forsteo-epar-scientific-discussion_en.pdf
h248,https://www.ema.europa.eu/documents/scientific-discussion/levitra-epar-scientific-discussion_en.pdf
h253,https://www.ema.europa.eu/documents/scientific-discussion/aldurazyme-epar-scientific-discussion_en.pdf
h085,https://www.ema.europa.eu/documents/scientific-discussion/karvezide-epar-scientific-discussion_en.pdf
h240,https://www.ema.europa.eu/documents/scientific-discussion/somavert-epar-scientific-discussion_en.pdf
h254,https://www.ema.europa.eu/documents/scientific-discussion/busilvex-epar-scientific-discussion_en.pdf
h255,https://www.ema.europa.eu/documents/scientific-discussion/ventavis-epar-scientific-discussion_en.pdf
h251,https://www.ema.europa.eu/documents/scientific-discussion/hepsera-epar-scientific-discussion_en.pdf
h262,https://www.ema.europa.eu/documents/scientific-discussion/emend-epar-scientific-discussion_en.pdf
h263,https://www.ema.europa.eu/documents/scientific-discussion/dukoral-epar-scientific-discussion_en.pdf
h261,https://www.ema.europa.eu/documents/scientific-discussion/emtriva-epar-scientific-discussion_en.pdf
h264,https://www.ema.europa.eu/documents/scientific-discussion/zevalin-epar-scientific-discussion_en.pdf
h214,https://www.ema.europa.eu/documents/scientific-discussion/kinzalkomb-epar-scientific-discussion_en.pdf
h269,https://www.ema.europa.eu/documents/assessment-report/faslodex-epar-public-assessment-report_en.pdf
h265,https://www.ema.europa.eu/documents/scientific-discussion/bonviva-epar-scientific-discussion_en.pdf
h252,https://www.ema.europa.eu/documents/scientific-discussion/fuzeon-epar-scientific-discussion_en.pdf
h642,https://www.ema.europa.eu/documents/assessment-report/ibandronic-acid-teva-epar-public-assessment-report_en.pdf
h270,https://www.ema.europa.eu/documents/scientific-discussion/kentera-epar-scientific-discussion_en.pdf
h268,https://www.ema.europa.eu/documents/scientific-discussion/cholestagel-epar-scientific-discussion_en.pdf
h256,https://www.ema.europa.eu/documents/scientific-discussion/humira-epar-scientific-discussion_en.pdf
h267,https://www.ema.europa.eu/documents/scientific-discussion/reyataz-epar-scientific-discussion_en.pdf
h639,https://www.ema.europa.eu/documents/assessment-report/telmisartan-actavis-epar-public-assessment-report_en.pdf
h643,https://www.ema.europa.eu/documents/assessment-report/rapiscan-epar-public-assessment-report_en.pdf
h641,https://www.ema.europa.eu/documents/assessment-report/ruconest-epar-public-assessment-report_en.pdf
h647,https://www.ema.europa.eu/documents/assessment-report/myclausen-epar-public-assessment-report_en.pdf
h648,https://www.ema.europa.eu/documents/assessment-report/twynsta-epar-public-assessment-report_en.pdf
h645,https://www.ema.europa.eu/documents/assessment-report/brinavess-epar-public-assessment-report_en.pdf
h654,https://www.ema.europa.eu/documents/assessment-report/leflunomide-ratiopharm-epar-public-assessment-report_en.pdf
h652,https://www.ema.europa.eu/documents/assessment-report/tobi-podhaler-epar-public-assessment-report_en.pdf
h659,https://www.ema.europa.eu/documents/assessment-report/iasibon-epar-public-assessment-report_en.pdf
h646,https://www.ema.europa.eu/documents/assessment-report/vpriv-epar-public-assessment-report_en.pdf
h658,https://www.ema.europa.eu/documents/assessment-report/aflunov-epar-public-assessment-report_en.pdf
h655,https://www.ema.europa.eu/documents/assessment-report/brilique-epar-public-assessment-report_en.pdf
h660,https://www.ema.europa.eu/documents/assessment-report/potactasol-epar-public-assessment-report_en.pdf
h665,https://www.ema.europa.eu/documents/assessment-report/entacapone-teva-epar-public-assessment-report_en.pdf
h644,https://www.ema.europa.eu/documents/assessment-report/pecfent-epar-public-assessment-report_en.pdf
h663,https://www.ema.europa.eu/documents/assessment-report/lamivudine/zidovudine-teva-epar-public-assessment-report_en.pdf
h667,https://www.ema.europa.eu/documents/assessment-report/esbriet-epar-public-assessment-report_en.pdf
h673,https://www.ema.europa.eu/documents/assessment-report/ifirmacombi-epar-public-assessment-report_en.pdf
h672,https://www.ema.europa.eu/documents/assessment-report/xeplion-epar-public-assessment-report_en.pdf
h870,https://www.ema.europa.eu/documents/assessment-report/orphacol-epar-public-assessment-report_en.pdf
h692,https://www.ema.europa.eu/documents/assessment-report/yellox-epar-public-assessment-report_en.pdf
h676,https://www.ema.europa.eu/documents/assessment-report/jevtana-epar-public-assessment-report_en.pdf
h637,https://www.ema.europa.eu/documents/assessment-report/leflunomide-medac-epar-public-assessment-report_en.pdf
h679,https://www.ema.europa.eu/documents/assessment-report/pravafenix-epar-public-assessment-report_en.pdf
h678,https://www.ema.europa.eu/documents/assessment-report/halaven-epar-public-assessment-report_en.pdf
h677,https://www.ema.europa.eu/documents/assessment-report/gilenya-epar-public-assessment-report_en.pdf
h669,https://www.ema.europa.eu/documents/assessment-report/teysuno-epar-public-assessment-report_en.pdf
h688,https://www.ema.europa.eu/documents/assessment-report/cinryze-epar-public-assessment-report_en.pdf
h697,https://www.ema.europa.eu/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf
h690,https://www.ema.europa.eu/documents/assessment-report/zoely-epar-public-assessment-report_en.pdf
h260,https://www.ema.europa.eu/documents/scientific-discussion/stalevo-epar-scientific-discussion_en.pdf
h640,https://www.ema.europa.eu/documents/assessment-report/sycrest-epar-public-assessment-report_en.pdf
h687,https://www.ema.europa.eu/documents/assessment-report/hizentra-epar-public-assessment-report_en.pdf
h702,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-ratiopharm-epar-public-assessment-report_en.pdf
h178,https://www.ema.europa.eu/documents/assessment-report/targretin-epar-public-assessment-report_en.pdf
h701,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-teva-epar-public-assessment-report_en.pdf
h700,https://www.ema.europa.eu/documents/assessment-report/benlysta-epar-public-assessment-report_en.pdf
h708,https://www.ema.europa.eu/documents/assessment-report/entacapone-orion-epar-public-assessment-report_en.pdf
h123,https://www.ema.europa.eu/documents/scientific-discussion/renagel-epar-scientific-discussion_en.pdf
h703,https://www.ema.europa.eu/documents/assessment-report/xgeva-epar-public-assessment-report_en.pdf
h712,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-accord-epar-public-assessment-report_en.pdf
h706,https://www.ema.europa.eu/documents/assessment-report/levodopa/carbidopa/entacapone-orion-epar-public-assessment-report_en.pdf
h710,https://www.ema.europa.eu/documents/assessment-report/votubia-epar-public-assessment-report_en.pdf
h713,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-actavis-epar-public-assessment-report_en.pdf
h709,https://www.ema.europa.eu/documents/assessment-report/buccolam-epar-public-assessment-report_en.pdf
h711,https://www.ema.europa.eu/documents/assessment-report/matever-epar-public-assessment-report_en.pdf
h707,https://www.ema.europa.eu/documents/assessment-report/trajenta-epar-public-assessment-report_en.pdf
h714,https://www.ema.europa.eu/documents/assessment-report/zytiga-epar-public-assessment-report_en.pdf
h717,https://www.ema.europa.eu/documents/assessment-report/vyndaqel-epar-public-assessment-report_en.pdf
h685,https://www.ema.europa.eu/documents/assessment-report/ibandronic-acid-sandoz-epar-public-assessment-report_en.pdf
h718,https://www.ema.europa.eu/documents/assessment-report/dexdor-epar-public-assessment-report_en.pdf
h682,https://www.ema.europa.eu/documents/assessment-report/methylthioninium-chloride-proveblue-epar-public-assessment-report_en.pdf
h715,https://www.ema.europa.eu/documents/assessment-report/plenadren-epar-public-assessment-report_en.pdf
h727,https://www.ema.europa.eu/documents/assessment-report/mercaptopurine-nova-laboratories-epar-public-assessment-report_en.pdf
h732,https://www.ema.europa.eu/documents/assessment-report/desloratadine-teva-epar-public-assessment-report_en.pdf
h722,https://www.ema.europa.eu/documents/assessment-report/pioglitazone-accord-epar-public-assessment-report_en.pdf
h716,https://www.ema.europa.eu/documents/assessment-report/eurartesim-epar-public-assessment-report_en.pdf
h719,https://www.ema.europa.eu/documents/assessment-report/telmisartan-teva-pharma-epar-public-assessment-report_en.pdf
h691,https://www.ema.europa.eu/documents/assessment-report/eliquis-epar-public-assessment-report_en.pdf
h737,https://www.ema.europa.eu/documents/assessment-report/eviplera-epar-public-assessment-report_en.pdf
h736,https://www.ema.europa.eu/documents/assessment-report/edurant-epar-public-assessment-report_en.pdf
h738,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-actavis-group-epar-public-assessment-report_en.pdf
h733,https://www.ema.europa.eu/documents/assessment-report/dificlir-epar-public-assessment-report_en.pdf
h739,https://www.ema.europa.eu/documents/assessment-report/dasselta-epar-public-assessment-report_en.pdf
h734,https://www.ema.europa.eu/documents/assessment-report/edarbi-epar-public-assessment-report_en.pdf
h731,https://www.ema.europa.eu/documents/assessment-report/komboglyze-epar-public-assessment-report_en.pdf
h745,https://www.ema.europa.eu/documents/assessment-report/desloratadine-actavis-epar-public-assessment-report_en.pdf
h699,https://www.ema.europa.eu/documents/assessment-report/fampyra-epar-public-assessment-report_en.pdf
h743,https://www.ema.europa.eu/documents/assessment-report/repaglinide-accord-epar-public-assessment-report_en.pdf
h740,https://www.ema.europa.eu/documents/assessment-report/ameluz-epar-public-assessment-report_en.pdf
h741,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-sun-epar-public-assessment-report_en.pdf
h746,https://www.ema.europa.eu/documents/assessment-report/desloratadine-ratiopharm-epar-public-assessment-report_en.pdf
h698,https://www.ema.europa.eu/documents/assessment-report/yervoy-epar-public-assessment-report_en.pdf
h751,https://www.ema.europa.eu/documents/assessment-report/zelboraf-epar-public-assessment-report_en.pdf
h753,https://www.ema.europa.eu/documents/assessment-report/signifor-epar-public-assessment-report_en.pdf
h749,https://www.ema.europa.eu/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
h694,https://www.ema.europa.eu/documents/assessment-report/nulojix-epar-public-assessment-report_en.pdf
h750,https://www.ema.europa.eu/documents/assessment-report/esmya-epar-public-assessment-report_en.pdf
h759,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-actavis-epar-public-assessment-report_en.pdf
h757,https://www.ema.europa.eu/documents/assessment-report/pioglitazone-teva-epar-public-assessment-report_en.pdf
h755,https://www.ema.europa.eu/documents/assessment-report/pioglitazone-actavis-epar-public-assessment-report_en.pdf
h764,https://www.ema.europa.eu/documents/assessment-report/pixuvri-epar-public-assessment-report_en.pdf
h771,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-teva-epar-public-assessment-report_en.pdf
h769,https://www.ema.europa.eu/documents/assessment-report/docetaxel-accord-epar-public-assessment-report_en.pdf
h747,https://www.ema.europa.eu/documents/assessment-report/colobreathe-epar-public-assessment-report_en.pdf
h768,https://www.ema.europa.eu/documents/assessment-report/riluzole-zentiva-epar-public-assessment-report_en.pdf
h761,https://www.ema.europa.eu/documents/assessment-report/capecitabine-teva-epar-public-assessment-report_en.pdf
h767,https://www.ema.europa.eu/documents/assessment-report/nimenrix-epar-public-assessment-report_en.pdf
h760,https://www.ema.europa.eu/documents/assessment-report/bronchitol-epar-public-assessment-report_en.pdf
h766,https://www.ema.europa.eu/documents/assessment-report/sancuso-epar-public-assessment-report_en.pdf
h777,https://www.ema.europa.eu/documents/assessment-report/inlyta-epar-public-assessment-report_en.pdf
h762,https://www.ema.europa.eu/documents/assessment-report/capecitabine-accord-epar-public-assessment-report_en.pdf
h742,https://www.ema.europa.eu/documents/assessment-report/efavirenz-teva-epar-public-assessment-report_en.pdf
h763,https://www.ema.europa.eu/documents/assessment-report/capecitabine-krka-epar-public-assessment-report_en.pdf
h770,https://www.ema.europa.eu/documents/assessment-report/docetaxel-kabi-epar-public-assessment-report_en.pdf
h775,https://www.ema.europa.eu/documents/assessment-report/novothirteen-epar-public-assessment-report_en.pdf
h773,https://www.ema.europa.eu/documents/assessment-report/jakavi-epar-public-assessment-report_en.pdf
h781,https://www.ema.europa.eu/documents/assessment-report/bretaris-genuair-epar-public-assessment-report_en.pdf
h779,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-medac-epar-public-assessment-report_en.pdf
h778,https://www.ema.europa.eu/documents/assessment-report/eklira-genuair-epar-public-assessment-report_en.pdf
h784,https://www.ema.europa.eu/documents/assessment-report/cuprymina-epar-public-assessment-report_en.pdf
h785,https://www.ema.europa.eu/documents/assessment-report/zinforo-epar-public-assessment-report_en.pdf
h776,https://www.ema.europa.eu/documents/assessment-report/fycompa-epar-public-assessment-report_en.pdf
h790,https://www.ema.europa.eu/documents/assessment-report/tovanor-breezhaler-epar-public-assessment-report_en.pdf
h787,https://www.ema.europa.eu/documents/assessment-report/revestive-epar-public-assessment-report_en.pdf
h786,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-mylan-epar-public-assessment-report_en.pdf
h783,https://www.ema.europa.eu/documents/assessment-report/zyclara-epar-public-assessment-report_en.pdf
h782,https://www.ema.europa.eu/documents/assessment-report/kalydeco-epar-public-assessment-report_en.pdf
h789,https://www.ema.europa.eu/documents/assessment-report/enurev-breezhaler-epar-public-assessment-report_en.pdf
h693,https://www.ema.europa.eu/documents/assessment-report/rivastigmine-actavis-epar-public-assessment-report_en.pdf
h788,https://www.ema.europa.eu/documents/assessment-report/seebri-breezhaler-epar-public-assessment-report_en.pdf
h798,https://www.ema.europa.eu/documents/assessment-report/ibandronic-acid-accord-epar-public-assessment-report_en.pdf
h799,https://www.ema.europa.eu/documents/assessment-report/memantine-merz-epar-public-assessment-report_en.pdf
h780,https://www.ema.europa.eu/documents/assessment-report/jentadueto-epar-public-assessment-report_en.pdf
h800,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-hospira-epar-public-assessment-report_en.pdf
h792,https://www.ema.europa.eu/documents/assessment-report/dacogen-epar-public-assessment-report_en.pdf
h803,https://www.ema.europa.eu/documents/assessment-report/nexobrid-epar-public-assessment-report_en.pdf
h801,https://www.ema.europa.eu/documents/assessment-report/constella-epar-public-assessment-report_en.pdf
h802,https://www.ema.europa.eu/documents/assessment-report/capecitabine-medac-epar-public-assessment-report_en.pdf
h794,https://www.ema.europa.eu/documents/assessment-report/adcetris-epar-public-assessment-report_en.pdf
h795,https://www.ema.europa.eu/documents/assessment-report/forxiga-epar-public-assessment-report_en.pdf
h793,https://www.ema.europa.eu/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf
h445,https://www.ema.europa.eu/documents/assessment-report/tevagrastim-epar-public-assessment-report_en.pdf
h797,https://www.ema.europa.eu/documents/assessment-report/eylea-epar-public-assessment-report_en.pdf
h808,https://www.ema.europa.eu/documents/assessment-report/imatinib-teva-epar-public-assessment-report_en.pdf
h807,https://www.ema.europa.eu/documents/assessment-report/tresiba-epar-public-assessment-report_en.pdf
h806,https://www.ema.europa.eu/documents/assessment-report/ryzodeg-epar-public-assessment-report_en.pdf
h448,https://www.ema.europa.eu/documents/assessment-report/mycamine-epar-public-assessment-report_en.pdf
h454,https://www.ema.europa.eu/documents/assessment-report/extavia-epar-public-assessment-report_en.pdf
h451,https://www.ema.europa.eu/documents/assessment-report/volibris-epar-public-assessment-report_en.pdf
h444,https://www.ema.europa.eu/documents/assessment-report/ratiograstim-epar-public-assessment-report_en.pdf
h805,https://www.ema.europa.eu/documents/assessment-report/amyvid-epar-public-assessment-report_en.pdf
h463,https://www.ema.europa.eu/documents/assessment-report/relistor-epar-public-assessment-report_en.pdf
h461,https://www.ema.europa.eu/documents/assessment-report/firazyr-epar-public-assessment-report_en.pdf
h469,https://www.ema.europa.eu/documents/assessment-report/oprymea-epar-public-assessment-report_en.pdf
h462,https://www.ema.europa.eu/documents/assessment-report/ranexa-epar-public-assessment-report_en.pdf
h466,https://www.ema.europa.eu/documents/assessment-report/bridion-epar-public-assessment-report_en.pdf
h468,https://www.ema.europa.eu/documents/assessment-report/intelence-epar-public-assessment-report_en.pdf
h475,https://www.ema.europa.eu/documents/assessment-report/olanzapine-mylan-epar-public-assessment-report_en.pdf
h482,https://www.ema.europa.eu/documents/assessment-report/azarga-epar-public-assessment-report_en.pdf
h483,https://www.ema.europa.eu/documents/assessment-report/zomarist-epar-public-assessment-report_en.pdf
h457,https://www.ema.europa.eu/documents/assessment-report/efficib-epar-public-assessment-report_en.pdf
h472,https://www.ema.europa.eu/documents/assessment-report/xarelto-epar-public-assessment-report_en.pdf
h470,https://www.ema.europa.eu/documents/assessment-report/vimpat-epar-public-assessment-report_en.pdf
h486,https://www.ema.europa.eu/documents/assessment-report/xiliarx-epar-public-assessment-report_en.pdf
h485,https://www.ema.europa.eu/documents/assessment-report/jalra-epar-public-assessment-report_en.pdf
h490,https://www.ema.europa.eu/documents/assessment-report/pramipexole-teva-epar-public-assessment-report_en.pdf
h480,https://www.ema.europa.eu/documents/assessment-report/ifirmasta-epar-public-assessment-report_en.pdf
h476,https://www.ema.europa.eu/documents/assessment-report/tadalafil-lilly-epar-public-assessment-report_en-0.pdf
h481,https://www.ema.europa.eu/documents/assessment-report/kuvan-epar-public-assessment-report_en.pdf
h477,https://www.ema.europa.eu/documents/assessment-report/ceplene-epar-public-assessment-report_en.pdf
h495,https://www.ema.europa.eu/documents/assessment-report/zarzio-epar-public-assessment-report_en.pdf
h496,https://www.ema.europa.eu/documents/assessment-report/filgrastim-hexal-epar-public-assessment-report_en.pdf
h498,https://www.ema.europa.eu/documents/assessment-report/thymanax-epar-public-assessment-report_en.pdf
h497,https://www.ema.europa.eu/documents/assessment-report/nplate-epar-public-assessment-report_en.pdf
h502,https://www.ema.europa.eu/documents/assessment-report/mepact-epar-public-assessment-report_en.pdf
h504,https://www.ema.europa.eu/documents/assessment-report/firmagon-epar-public-assessment-report_en.pdf
h499,https://www.ema.europa.eu/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf
h492,https://www.ema.europa.eu/documents/assessment-report/roactemra-epar-public-assessment-report_en.pdf
h503,https://www.ema.europa.eu/documents/assessment-report/efient-epar-public-assessment-report_en.pdf
h508,https://www.ema.europa.eu/documents/assessment-report/synflorix-epar-public-assessment-report_en.pdf
h455,https://www.ema.europa.eu/documents/assessment-report/janumet-epar-public-assessment-report_en.pdf
h456,https://www.ema.europa.eu/documents/assessment-report/velmetia-epar-public-assessment-report_en.pdf
h465,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-winthrop-epar-public-assessment-report_en.pdf
h516,https://www.ema.europa.eu/documents/assessment-report/somac-control-epar-public-assessment-report_en.pdf
h479,https://www.ema.europa.eu/documents/assessment-report/zypadhera-epar-public-assessment-report_en.pdf
h524,https://www.ema.europa.eu/documents/assessment-report/qutenza-epar-public-assessment-report_en.pdf
h515,https://www.ema.europa.eu/documents/assessment-report/controloc-control-epar-public-assessment-report_en.pdf
h523,https://www.ema.europa.eu/documents/assessment-report/modigraf-epar-public-assessment-report_en.pdf
h526,https://www.ema.europa.eu/documents/assessment-report/iressa-epar-public-assessment-report_en.pdf
h514,https://www.ema.europa.eu/documents/assessment-report/zebinix-epar-public-assessment-report_en.pdf
h488,https://www.ema.europa.eu/documents/assessment-report/vidaza-epar-public-assessment-report_en.pdf
h525,https://www.ema.europa.eu/documents/assessment-report/nimvastid-epar-public-assessment-report_en.pdf
h522,https://www.ema.europa.eu/documents/assessment-report/ellaone-epar-public-assessment-report_en.pdf
h521,https://www.ema.europa.eu/documents/assessment-report/renvela-epar-public-assessment-report_en.pdf
h528,https://www.ema.europa.eu/documents/assessment-report/nymusa-epar-public-assessment-report_en.pdf
h530,https://www.ema.europa.eu/documents/assessment-report/repaglinide-teva-epar-public-assessment-report_en.pdf
h533,https://www.ema.europa.eu/documents/assessment-report/vedrop-epar-public-assessment-report_en.pdf
h535,https://www.ema.europa.eu/documents/assessment-report/grepid-epar-public-assessment-report_en.pdf
h501,https://www.ema.europa.eu/documents/assessment-report/ixiaro-epar-public-assessment-report_en.pdf
h494,https://www.ema.europa.eu/documents/assessment-report/stelara-epar-public-assessment-report_en.pdf
h531,https://www.ema.europa.eu/documents/assessment-report/instanyl-epar-public-assessment-report_en.pdf
h529,https://www.ema.europa.eu/documents/assessment-report/victoza-epar-public-assessment-report_en.pdf
h537,https://www.ema.europa.eu/documents/assessment-report/mozobil-epar-public-assessment-report_en.pdf
h540,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-teva-hydrogen-sulphate-epar-public-assessment-report_en.pdf
h538,https://www.ema.europa.eu/documents/assessment-report/afinitor-epar-public-assessment-report_en.pdf
h545,https://www.ema.europa.eu/documents/assessment-report/onglyza-epar-public-assessment-report_en.pdf
h546,https://www.ema.europa.eu/documents/assessment-report/simponi-epar-public-assessment-report_en.pdf
h555,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-tad-epar-public-assessment-report_en.pdf
h553,https://www.ema.europa.eu/documents/assessment-report/zyllt-epar-public-assessment-report_en.pdf
h562,https://www.ema.europa.eu/documents/assessment-report/zopya-epar-public-assessment-report_en.pdf
h558,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-bgr-previously-zylagren-epar-public-assessment-report_en.pdf
h566,https://www.ema.europa.eu/documents/assessment-report/lamivudine-teva-epar-public-assessment-report_en.pdf
h556,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-krka-epar-public-assessment-report_en.pdf
h565,https://www.ema.europa.eu/documents/assessment-report/biopoin-epar-public-assessment-report_en.pdf
h573,https://www.ema.europa.eu/documents/assessment-report/eporatio-epar-public-assessment-report_en.pdf
h543,https://www.ema.europa.eu/documents/assessment-report/cayston-epar-public-assessment-report_en.pdf
h564,https://www.ema.europa.eu/documents/assessment-report/ilaris-epar-public-assessment-report_en.pdf
h551,https://www.ema.europa.eu/documents/assessment-report/vizarsin-epar-public-assessment-report_en.pdf
h572,https://www.ema.europa.eu/documents/assessment-report/alendronate-sodium/colecalciferol-msd-epar-public-assessment-report_en.pdf
h539,https://www.ema.europa.eu/documents/assessment-report/samsca-epar-public-assessment-report_en.pdf
h581,https://www.ema.europa.eu/documents/assessment-report/resolor-epar-public-assessment-report_en.pdf
h569,https://www.ema.europa.eu/documents/assessment-report/exforge-hct-epar-public-assessment-report_en.pdf
h576,https://www.ema.europa.eu/documents/assessment-report/irbesartan-teva-epar-public-assessment-report_en.pdf
h571,https://www.ema.europa.eu/documents/assessment-report/pandemic-influenza-vaccine-h5n1-baxter-epar-public-assessment-report_en.pdf
h544,https://www.ema.europa.eu/documents/assessment-report/cimzia-epar-public-assessment-report_en.pdf
h583,https://www.ema.europa.eu/documents/assessment-report/irbesartan/hydrochlorothiazide-teva-epar-public-assessment-report_en.pdf
h575,https://www.ema.europa.eu/documents/assessment-report/copalia-hct-epar-public-assessment-report_en.pdf
h580,https://www.ema.europa.eu/documents/assessment-report/enyglid-epar-public-assessment-report_en.pdf
h586,https://www.ema.europa.eu/documents/assessment-report/oslif-breezhaler-epar-public-assessment-report_en.pdf
h589,https://www.ema.europa.eu/documents/assessment-report/rivastigmine-hexal-epar-public-assessment-report_en.pdf
h584,https://www.ema.europa.eu/documents/assessment-report/sildenafil-teva-epar-public-assessment-report_en.pdf
h588,https://www.ema.europa.eu/documents/assessment-report/olanzapine-glenmark-europe-epar-public-assessment-report_en.pdf
h587,https://www.ema.europa.eu/documents/assessment-report/olanzapine-glenmark-epar-public-assessment-report_en.pdf
h550,https://www.ema.europa.eu/documents/assessment-report/javlor-epar-public-assessment-report_en.pdf
h473,https://www.ema.europa.eu/documents/assessment-report/evicel-epar-public-assessment-report_en.pdf
h597,https://www.ema.europa.eu/documents/assessment-report/olazax-epar-public-assessment-report_en.pdf
h593,https://www.ema.europa.eu/documents/assessment-report/onbrez-breezhaler-epar-public-assessment-report_en.pdf
h590,https://www.ema.europa.eu/documents/assessment-report/prevenar-13-epar-public-assessment-report_en.pdf
h599,https://www.ema.europa.eu/documents/assessment-report/rivastigmine-sandoz-epar-public-assessment-report_en.pdf
h598,https://www.ema.europa.eu/documents/assessment-report/nevirapine-teva-epar-public-assessment-report_en.pdf
h577,https://www.ema.europa.eu/documents/assessment-report/foclivia-epar-public-assessment-report_en.pdf
h484,https://www.ema.europa.eu/documents/assessment-report/icandra-epar-public-assessment-report_en.pdf
h596,https://www.ema.europa.eu/documents/assessment-report/lamivudine-teva-pharma-bv-epar-public-assessment-report_en.pdf
h600,https://www.ema.europa.eu/documents/assessment-report/zutectra-epar-public-assessment-report_en.pdf
h511,https://www.ema.europa.eu/documents/assessment-report/conbriza-epar-public-assessment-report_en.pdf
h594,https://www.ema.europa.eu/documents/assessment-report/hirobriz-breezhaler-epar-public-assessment-report_en.pdf
h604,https://www.ema.europa.eu/documents/assessment-report/leflunomide-winthrop-epar-public-assessment-report_en.pdf
h595,https://www.ema.europa.eu/documents/assessment-report/sildenafil-actavis-epar-public-assessment-report_en.pdf
h602,https://www.ema.europa.eu/documents/assessment-report/scintimun-epar-public-assessment-report_en.pdf
h601,https://www.ema.europa.eu/documents/assessment-report/firdapse-epar-public-assessment-report_en.pdf
h609,https://www.ema.europa.eu/documents/assessment-report/elonva-epar-public-assessment-report_en.pdf
h606,https://www.ema.europa.eu/documents/assessment-report/temozolomide-teva-epar-public-assessment-report_en.pdf
h607,https://www.ema.europa.eu/documents/assessment-report/silodyx-epar-public-assessment-report_en.pdf
h618,https://www.ema.europa.eu/documents/assessment-report/prolia-epar-public-assessment-report_en.pdf
h608,https://www.ema.europa.eu/documents/assessment-report/urorec-epar-public-assessment-report_en.pdf
h619,https://www.ema.europa.eu/documents/assessment-report/duoplavin-epar-public-assessment-report_en.pdf
h614,https://www.ema.europa.eu/documents/assessment-report/menveo-epar-public-assessment-report_en.pdf
h627,https://www.ema.europa.eu/documents/assessment-report/raloxifene-teva-epar-public-assessment-report_en.pdf
h622,https://www.ema.europa.eu/documents/assessment-report/tepadina-epar-public-assessment-report_en.pdf
h620,https://www.ema.europa.eu/documents/assessment-report/ristfor-epar-public-assessment-report_en.pdf
h628,https://www.ema.europa.eu/documents/assessment-report/votrient-epar-public-assessment-report_en.pdf
h635,https://www.ema.europa.eu/documents/assessment-report/olanzapine-apotex-epar-public-assessment-report_en.pdf
h632,https://www.ema.europa.eu/documents/assessment-report/tolura-epar-public-assessment-report_en.pdf
h612,https://www.ema.europa.eu/documents/assessment-report/revolade-epar-public-assessment-report_en.pdf
h633,https://www.ema.europa.eu/documents/assessment-report/topotecan-hospira-epar-public-assessment-report_en.pdf
h592,https://www.ema.europa.eu/documents/assessment-report/olazax-disperzi-epar-public-assessment-report_en.pdf
h517,https://www.ema.europa.eu/documents/assessment-report/pantozol-control-epar-public-assessment-report_en.pdf
h621,https://www.ema.europa.eu/documents/assessment-report/ristaben-epar-public-assessment-report_en.pdf
h636,https://www.ema.europa.eu/documents/assessment-report/daxas-epar-public-assessment-report_en.pdf
h591,https://www.ema.europa.eu/documents/assessment-report/multaq-epar-public-assessment-report_en.pdf
h1298,https://www.ema.europa.eu/documents/assessment-report/veyvondi-epar-public-assessment-report_en.pdf
h1076,https://www.ema.europa.eu/documents/assessment-report/kovaltry-epar-public-assessment-report_en.pdf
h1078,https://www.ema.europa.eu/documents/assessment-report/natpar-epar-public-assessment-report_en.pdf
h1086,https://www.ema.europa.eu/documents/assessment-report/tagrisso-epar-public-assessment-report_en.pdf
h638,https://www.ema.europa.eu/documents/assessment-report/ozurdex-epar-public-assessment-report_en.pdf
h1025,https://www.ema.europa.eu/documents/assessment-report/evotaz-epar-public-assessment-report_en.pdf
h1273,https://www.ema.europa.eu/documents/assessment-report/prasugrel-mylan-epar-public-assessment-report_en.pdf
h946,https://www.ema.europa.eu/documents/assessment-report/accofil-epar-public-assessment-report_en.pdf
h819,https://www.ema.europa.eu/documents/assessment-report/jetrea-epar-public-assessment-report_en.pdf
h945,https://www.ema.europa.eu/documents/assessment-report/imbruvica-epar-public-assessment-report_en.pdf
h809,https://www.ema.europa.eu/documents/assessment-report/betmiga-epar-public-assessment-report_en.pdf
h844,https://www.ema.europa.eu/documents/assessment-report/vipidia-epar-public-assessment-report_en.pdf
h884,https://www.ema.europa.eu/documents/assessment-report/invokana-epar-public-assessment-report_en.pdf
h842,https://www.ema.europa.eu/documents/assessment-report/incresync-epar-public-assessment-report_en.pdf
h894,https://www.ema.europa.eu/documents/assessment-report/sovaldi-epar-public-assessment-report_en.pdf
h841,https://www.ema.europa.eu/documents/assessment-report/spedra-epar-public-assessment-report_en.pdf
h812,https://www.ema.europa.eu/documents/assessment-report/bexsero-epar-public-assessment-report_en.pdf
h918,https://www.ema.europa.eu/documents/assessment-report/vokanamet-epar-public-assessment-report_en.pdf
h862,https://www.ema.europa.eu/documents/assessment-report/ultibro-breezhaler-epar-public-assessment-report_en.pdf
h858,https://www.ema.europa.eu/documents/assessment-report/stivarga-epar-public-assessment-report_en.pdf
h904,https://www.ema.europa.eu/documents/assessment-report/mirvaso-epar-public-assessment-report_en.pdf
h863,https://www.ema.europa.eu/documents/assessment-report/xoterna-breezhaler-epar-public-assessment-report_en.pdf
h878,https://www.ema.europa.eu/documents/assessment-report/defitelio-epar-public-assessment-report_en.pdf
h882,https://www.ema.europa.eu/documents/assessment-report/abilify-maintena-epar-public-assessment-report_en.pdf
h981,https://www.ema.europa.eu/documents/assessment-report/otezla-epar-public-assessment-report_en.pdf
h865,https://www.ema.europa.eu/documents/assessment-report/tafinlar-epar-public-assessment-report_en.pdf
h843,https://www.ema.europa.eu/documents/assessment-report/vipdomet-epar-public-assessment-report_en.pdf
h888,https://www.ema.europa.eu/documents/assessment-report/novoeight-epar-public-assessment-report_en.pdf
h875,https://www.ema.europa.eu/documents/assessment-report/deltyba-epar-public-assessment-report_en.pdf
h980,https://www.ema.europa.eu/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf
h631,https://www.ema.europa.eu/documents/assessment-report/nivestim-epar-public-assessment-report_en.pdf
h837,https://www.ema.europa.eu/documents/assessment-report/tecfidera-epar-public-assessment-report_en.pdf
h838,https://www.ema.europa.eu/documents/assessment-report/aubagio-epar-public-assessment-report_en.pdf
h923,https://www.ema.europa.eu/documents/assessment-report/entyvio-epar-public-assessment-report_en.pdf
h913,https://www.ema.europa.eu/documents/assessment-report/latuda-epar-public-assessment-report_en.pdf
h901,https://www.ema.europa.eu/documents/assessment-report/sirturo-epar-public-assessment-report_en.pdf
h915,https://www.ema.europa.eu/documents/assessment-report/ebilfumin-epar-public-assessment-report_en.pdf
h929,https://www.ema.europa.eu/documents/assessment-report/revinty-ellipta-epar-public-assessment-report_en.pdf
h877,https://www.ema.europa.eu/documents/assessment-report/grastofil-epar-public-assessment-report_en.pdf
h834,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-accord-epar-public-assessment-report_en.pdf
h931,https://www.ema.europa.eu/documents/assessment-report/mekinist-epar-public-assessment-report_en.pdf
h825,https://www.ema.europa.eu/documents/assessment-report/imatinib-actavis-epar-public-assessment-report_en.pdf
h920,https://www.ema.europa.eu/documents/assessment-report/duoresp-spiromax-epar-public-assessment-report_en.pdf
h873,https://www.ema.europa.eu/documents/assessment-report/xofigo-epar-public-assessment-report_en.pdf
h820,https://www.ema.europa.eu/documents/assessment-report/maruxa-epar-public-assessment-report_en.pdf
h579,https://www.ema.europa.eu/documents/assessment-report/repaglinide-krka-epar-public-assessment-report_en.pdf
h969,https://www.ema.europa.eu/documents/assessment-report/scenesse-epar-public-assessment-report_en.pdf
h824,https://www.ema.europa.eu/documents/assessment-report/nemdatine-epar-public-assessment-report_en.pdf
h817,https://www.ema.europa.eu/documents/assessment-report/actelsar-hct-epar-public-assessment-report_en.pdf
h832,https://www.ema.europa.eu/documents/assessment-report/stayveer-epar-public-assessment-report_en.pdf
h840,https://www.ema.europa.eu/documents/assessment-report/hyqvia-epar-public-assessment-report_en.pdf
h856,https://www.ema.europa.eu/documents/assessment-report/lonquex-epar-public-assessment-report_en.pdf
h574,https://www.ema.europa.eu/documents/assessment-report/dafiro-hct-epar-public-assessment-report_en.pdf
h829,https://www.ema.europa.eu/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf
h892,https://www.ema.europa.eu/documents/assessment-report/tivicay-epar-public-assessment-report_en.pdf
h828,https://www.ema.europa.eu/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf
h818,https://www.ema.europa.eu/documents/assessment-report/bosulif-epar-public-assessment-report_en.pdf
h879,https://www.ema.europa.eu/documents/assessment-report/giotrif-epar-public-assessment-report_en.pdf
h811,https://www.ema.europa.eu/documents/assessment-report/lyxumia-epar-public-assessment-report_en.pdf
h963,https://www.ema.europa.eu/documents/assessment-report/brimica-genuair-epar-public-assessment-report_en.pdf
h848,https://www.ema.europa.eu/documents/assessment-report/erivedge-epar-public-assessment-report_en.pdf
h902,https://www.ema.europa.eu/documents/assessment-report/translarna-epar-public-assessment-report_en.pdf
h930,https://www.ema.europa.eu/documents/assessment-report/jardiance-epar-public-assessment-report_en.pdf
h814,https://www.ema.europa.eu/documents/assessment-report/zaltrap-epar-public-assessment-report_en.pdf
h860,https://www.ema.europa.eu/documents/assessment-report/nexium-control-epar-public-assessment-report_en.pdf
h943,https://www.ema.europa.eu/documents/assessment-report/velphoro-epar-public-assessment-report_en.pdf
h964,https://www.ema.europa.eu/documents/assessment-report/duaklir-genuair-epar-public-assessment-report_en.pdf
h822,https://www.ema.europa.eu/documents/assessment-report/pheburane-epar-public-assessment-report_en.pdf
h899,https://www.ema.europa.eu/documents/assessment-report/laventair-epar-public-assessment-report_en.pdf
h887,https://www.ema.europa.eu/documents/assessment-report/fluenz-tetra-epar-public-assessment-report_en.pdf
h861,https://www.ema.europa.eu/documents/assessment-report/procysbi-epar-public-assessment-report_en.pdf
h881,https://www.ema.europa.eu/documents/assessment-report/lidocaine/prilocaine-plethora-epar-public-assessment-report_en.pdf
h821,https://www.ema.europa.eu/documents/assessment-report/tolucombi-epar-public-assessment-report_en.pdf
h914,https://www.ema.europa.eu/documents/assessment-report/vimizim-epar-public-assessment-report_en.pdf
h967,https://www.ema.europa.eu/documents/assessment-report/rezolsta-epar-public-assessment-report_en.pdf
h859,https://www.ema.europa.eu/documents/assessment-report/levodopa/carbidopa/entacapone-sandoz-epar-public-assessment-report_en.pdf
h919,https://www.ema.europa.eu/documents/assessment-report/hemangiol-epar-public-assessment-report_en.pdf
h852,https://www.ema.europa.eu/documents/assessment-report/atosiban-sun-epar-public-assessment-report_en.pdf
h866,https://www.ema.europa.eu/documents/assessment-report/cholib-epar-public-assessment-report_en.pdf
h896,https://www.ema.europa.eu/documents/assessment-report/para-aminosalicylic-acid-lucane-epar-public-assessment-report_en.pdf
h955,https://www.ema.europa.eu/documents/assessment-report/lymphoseek-epar-public-assessment-report_en.pdf
h935,https://www.ema.europa.eu/documents/assessment-report/envarsus-epar-public-assessment-report_en.pdf
h975,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-ratiopharm-epar-public-assessment-report_en-0.pdf
h880,https://www.ema.europa.eu/documents/assessment-report/memantine-accord-epar-public-assessment-report_en.pdf
h855,https://www.ema.europa.eu/documents/assessment-report/imvanex-epar-public-assessment-report_en.pdf
h815,https://www.ema.europa.eu/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf
h916,https://www.ema.europa.eu/documents/assessment-report/pregabalin-pfizer-epar-public-assessment-report_en.pdf
h850,https://www.ema.europa.eu/documents/assessment-report/pomalidomide-celgene-epar-public-assessment-report_en.pdf
h889,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-hospira-epar-public-assessment-report_en.pdf
h823,https://www.ema.europa.eu/documents/assessment-report/adasuve-epar-public-assessment-report_en.pdf
h954,https://www.ema.europa.eu/documents/assessment-report/vargatef-epar-public-assessment-report_en.pdf
h974,https://www.ema.europa.eu/documents/assessment-report/cerdelga-epar-public-assessment-report_en.pdf
h857,https://www.ema.europa.eu/documents/assessment-report/voncento-epar-public-assessment-report_en.pdf
h813,https://www.ema.europa.eu/documents/assessment-report/perjeta-epar-public-assessment-report_en.pdf
h940,https://www.ema.europa.eu/documents/assessment-report/triumeq-epar-public-assessment-report_en.pdf
h957,https://www.ema.europa.eu/documents/assessment-report/cyramza-epar-public-assessment-report_en.pdf
h603,https://www.ema.europa.eu/documents/assessment-report/sildenafil-ratiopharm-epar-public-assessment-report_en.pdf
h906,https://www.ema.europa.eu/documents/assessment-report/neuraceq-epar-public-assessment-report_en.pdf
h891,https://www.ema.europa.eu/documents/assessment-report/brintellix-epar-public-assessment-report_en.pdf
h965,https://www.ema.europa.eu/documents/assessment-report/ketoconazole-hra-epar-public-assessment-report_en.pdf
h956,https://www.ema.europa.eu/documents/assessment-report/trulicity-epar-public-assessment-report_en.pdf
h951,https://www.ema.europa.eu/documents/assessment-report/busulfan-fresenius-kabi-epar-public-assessment-report_en.pdf
h970,https://www.ema.europa.eu/documents/assessment-report/rixubis-epar-public-assessment-report_en.pdf
h890,https://www.ema.europa.eu/documents/assessment-report/cometriq-epar-public-assessment-report_en.pdf
h977,https://www.ema.europa.eu/documents/assessment-report/rasagiline-ratiopharm-epar-public-assessment-report_en.pdf
h830,https://www.ema.europa.eu/documents/assessment-report/stribild-epar-public-assessment-report_en.pdf
h893,https://www.ema.europa.eu/documents/assessment-report/opsumit-epar-public-assessment-report_en.pdf
h826,https://www.ema.europa.eu/documents/assessment-report/memantine-lek-epar-public-assessment-report_en.pdf
h972,https://www.ema.europa.eu/documents/assessment-report/duloxetine-lilly-epar-public-assessment-report_en.pdf
h973,https://www.ema.europa.eu/documents/assessment-report/quinsair-epar-public-assessment-report_en.pdf
h978,https://www.ema.europa.eu/documents/assessment-report/senshio-epar-public-assessment-report_en.pdf
h934,https://www.ema.europa.eu/documents/assessment-report/plegridy-epar-public-assessment-report_en.pdf
h933,https://www.ema.europa.eu/documents/assessment-report/simbrinza-epar-public-assessment-report_en.pdf
h936,https://www.ema.europa.eu/documents/assessment-report/nuwiq-epar-public-assessment-report_en.pdf
h869,https://www.ema.europa.eu/documents/assessment-report/lemtrada-epar-public-assessment-report_en.pdf
h846,https://www.ema.europa.eu/documents/assessment-report/xtandi-epar-public-assessment-report_en.pdf
h845,https://www.ema.europa.eu/documents/assessment-report/imatinib-accord-epar-public-assessment-report_en.pdf
h928,https://www.ema.europa.eu/documents/assessment-report/sylvant-epar-public-assessment-report_en.pdf
h836,https://www.ema.europa.eu/documents/assessment-report/memantine-ratiopharm-epar-public-assessment-report_en.pdf
h960,https://www.ema.europa.eu/documents/assessment-report/duavive-epar-public-assessment-report_en.pdf
h853,https://www.ema.europa.eu/documents/assessment-report/remsima-epar-public-assessment-report_en-0.pdf
h854,https://www.ema.europa.eu/documents/assessment-report/inflectra-epar-public-assessment-report_en.pdf
h871,https://www.ema.europa.eu/documents/assessment-report/ovaleap-epar-public-assessment-report_en.pdf
h961,https://www.ema.europa.eu/documents/assessment-report/tadalafil-mylan-epar-public-assessment-report_en.pdf
h959,https://www.ema.europa.eu/documents/assessment-report/lynparza-epar-public-assessment-report_en.pdf
h952,https://www.ema.europa.eu/documents/assessment-report/sevelamer-carbonate-zentiva-epar-public-assessment-report_en.pdf
h827,https://www.ema.europa.eu/documents/assessment-report/memantine-mylan-epar-public-assessment-report_en.pdf
h917,https://www.ema.europa.eu/documents/assessment-report/ulunar-breezhaler-epar-public-assessment-report_en.pdf
h886,https://www.ema.europa.eu/documents/assessment-report/relvar-ellipta-epar-public-assessment-report_en.pdf
h938,https://www.ema.europa.eu/documents/assessment-report/zydelig-epar-public-assessment-report_en.pdf
h937,https://www.ema.europa.eu/documents/assessment-report/gazyvaro-epar-public-assessment-report_en.pdf
h851,https://www.ema.europa.eu/documents/assessment-report/lojuxta-epar-public-assessment-report_en.pdf
h921,https://www.ema.europa.eu/documents/assessment-report/biresp-spiromax-epar-public-assessment-report_en.pdf
h909,https://www.ema.europa.eu/documents/assessment-report/bemfola-epar-public-assessment-report_en.pdf
h905,https://www.ema.europa.eu/documents/assessment-report/izba-epar-public-assessment-report_en.pdf
h872,https://www.ema.europa.eu/documents/assessment-report/tybost-epar-public-assessment-report_en.pdf
h1056,https://www.ema.europa.eu/documents/assessment-report/praxbind-epar-public-assessment-report_en.pdf
h958,https://www.ema.europa.eu/documents/assessment-report/harvoni-epar-public-assessment-report_en.pdf
h885,https://www.ema.europa.eu/documents/assessment-report/kadcyla-epar-public-assessment-report_en.pdf
h947,https://www.ema.europa.eu/documents/assessment-report/xultophy-epar-public-assessment-report_en.pdf
h962,https://www.ema.europa.eu/documents/assessment-report/moventig-epar-public-assessment-report_en.pdf
h941,https://www.ema.europa.eu/documents/assessment-report/vizamyl-epar-public-assessment-report_en.pdf
h835,https://www.ema.europa.eu/documents/assessment-report/voriconazole-accord-epar-public-assessment-report_en.pdf
h999,https://www.ema.europa.eu/documents/assessment-report/zykadia-epar-public-assessment-report_en.pdf
h900,https://www.ema.europa.eu/documents/assessment-report/xigduo-epar-public-assessment-report_en.pdf
h1010,https://www.ema.europa.eu/documents/assessment-report/duloxetine-mylan-epar-public-assessment-report_en.pdf
h1013,https://www.ema.europa.eu/documents/assessment-report/lumark-epar-public-assessment-report_en.pdf
h997,https://www.ema.europa.eu/documents/assessment-report/pregabalin-mylan-epar-public-assessment-report_en.pdf
h1053,https://www.ema.europa.eu/documents/assessment-report/neofordex-epar-public-assessment-report_en.pdf
h1015,https://www.ema.europa.eu/documents/assessment-report/strensiq-epar-public-assessment-report_en.pdf
h1006,https://www.ema.europa.eu/documents/assessment-report/respreeza-epar-public-assessment-report_en.pdf
h1009,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-zentiva-epar-public-assessment-report_en.pdf
h1001,https://www.ema.europa.eu/documents/assessment-report/akynzeo-epar-public-assessment-report_en.pdf
h1018,https://www.ema.europa.eu/documents/assessment-report/omidria-epar-public-assessment-report_en.pdf
h1019,https://www.ema.europa.eu/documents/assessment-report/bortezomib-accord-epar-public-assessment-report_en.pdf
h1014,https://www.ema.europa.eu/documents/assessment-report/opdivo-epar-public-assessment-report_en.pdf
h1011,https://www.ema.europa.eu/documents/assessment-report/pregabalin-sandoz-epar-public-assessment-report_en.pdf
h979,https://www.ema.europa.eu/documents/assessment-report/ofev-epar-public-assessment-report_en.pdf
h1020,https://www.ema.europa.eu/documents/assessment-report/raxone-epar-public-assessment-report_en.pdf
h1045,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-accord-epar-public-assessment-report_en.pdf
h1046,https://www.ema.europa.eu/documents/assessment-report/elocta-epar-public-assessment-report_en.pdf
h1043,https://www.ema.europa.eu/documents/assessment-report/nucala-epar-public-assessment-report_en.pdf
h1047,https://www.ema.europa.eu/documents/assessment-report/blincyto-epar-public-assessment-report_en.pdf
h1049,https://www.ema.europa.eu/documents/assessment-report/cystadrops-epar-public-assessment-report_en.pdf
h907,https://www.ema.europa.eu/documents/assessment-report/adempas-epar-public-assessment-report_en.pdf
h1048,https://www.ema.europa.eu/documents/assessment-report/cotellic-epar-public-assessment-report_en.pdf
h1051,https://www.ema.europa.eu/documents/assessment-report/ebymect-epar-public-assessment-report_en.pdf
h984,https://www.ema.europa.eu/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf
h1008,https://www.ema.europa.eu/documents/assessment-report/hetlioz-epar-public-assessment-report_en.pdf
h989,https://www.ema.europa.eu/documents/assessment-report/tenkasi-previously-orbactiv-epar-public-assessment-report_en.pdf
h615,https://www.ema.europa.eu/documents/assessment-report/temozolomide-hospira-epar-public-assessment-report_en.pdf
h1005,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-pharmathen-epar-public-assessment-report_en.pdf
h1007,https://www.ema.europa.eu/documents/assessment-report/gardasil-9-epar-public-assessment-report_en.pdf
h133,https://www.ema.europa.eu/documents/scientific-discussion/optisulin-epar-scientific-discussion_en.pdf
h1097,https://www.ema.europa.eu/documents/assessment-report/strimvelis-epar-public-assessment-report_en.pdf
h1052,https://www.ema.europa.eu/documents/assessment-report/edistride-epar-public-assessment-report_en.pdf
h991,https://www.ema.europa.eu/documents/assessment-report/sivextro-epar-public-assessment-report_en.pdf
h1061,https://www.ema.europa.eu/documents/assessment-report/genvoya-epar-public-assessment-report_en.pdf
h986,https://www.ema.europa.eu/documents/assessment-report/xydalba-epar-public-assessment-report_en.pdf
h1000,https://www.ema.europa.eu/documents/assessment-report/jinarc-epar-public-assessment-report_en.pdf
h1065,https://www.ema.europa.eu/documents/assessment-report/eptifibatide-accord-epar-public-assessment-report_en.pdf
h1067,https://www.ema.europa.eu/documents/assessment-report/lopinavir/ritonavir-mylan-epar-public-assessment-report_en.pdf
h994,https://www.ema.europa.eu/documents/assessment-report/kengrexal-epar-public-assessment-report_en.pdf
h987,https://www.ema.europa.eu/documents/assessment-report/holoclar-epar-public-assessment-report_en.pdf
h1073,https://www.ema.europa.eu/documents/assessment-report/briviact-epar-public-assessment-report_en.pdf
h1071,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-accord-epar-public-assessment-report_en.pdf
h1055,https://www.ema.europa.eu/documents/assessment-report/ciambra-epar-public-assessment-report_en.pdf
h1092,https://www.ema.europa.eu/documents/assessment-report/amlodipine/valsartan-mylan-epar-public-assessment-report_en.pdf
h1036,https://www.ema.europa.eu/documents/assessment-report/cresemba-epar-public-assessment-report_en.pdf
h1072,https://www.ema.europa.eu/documents/assessment-report/spectrila-epar-public-assessment-report_en.pdf
h1031,https://www.ema.europa.eu/documents/assessment-report/praluent-epar-public-assessment-report_en.pdf
h1103,https://www.ema.europa.eu/documents/assessment-report/neparvis-epar-public-assessment-report_en.pdf
h944,https://www.ema.europa.eu/documents/assessment-report/abasria-epar-public-assessment-report_en.pdf
h1032,https://www.ema.europa.eu/documents/assessment-report/zerbaxa-epar-public-assessment-report_en.pdf
h1059,https://www.ema.europa.eu/documents/assessment-report/orkambi-epar-public-assessment-report_en.pdf
h1098,https://www.ema.europa.eu/documents/assessment-report/alprolix-epar-public-assessment-report_en.pdf
h1060,https://www.ema.europa.eu/documents/assessment-report/kyprolis-epar-public-assessment-report_en.pdf
h1064,https://www.ema.europa.eu/documents/assessment-report/imlygic-epar-public-assessment-report_en.pdf
h1099,https://www.ema.europa.eu/documents/assessment-report/descovy-epar-public-assessment-report_en.pdf
h1102,https://www.ema.europa.eu/documents/assessment-report/bortezomib-sun-epar-public-assessment-report_en.pdf
h1029,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-sandoz-epar-public-assessment-report_en.pdf
h1087,https://www.ema.europa.eu/documents/assessment-report/coagadex-epar-public-assessment-report_en.pdf
h1040,https://www.ema.europa.eu/documents/assessment-report/intuniv-epar-public-assessment-report_en.pdf
h1088,https://www.ema.europa.eu/documents/assessment-report/empliciti-epar-public-assessment-report_en.pdf
h1094,https://www.ema.europa.eu/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf
h1093,https://www.ema.europa.eu/documents/assessment-report/zonisamide-mylan-epar-public-assessment-report_en.pdf
h1041,https://www.ema.europa.eu/documents/assessment-report/ivabradine-anpharm-epar-public-assessment-report_en.pdf
h1096,https://www.ema.europa.eu/documents/assessment-report/lonsurf-epar-public-assessment-report_en.pdf
h1063,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-actavis-epar-public-assessment-report_en.pdf
h988,https://www.ema.europa.eu/documents/assessment-report/mysimba-epar-public-assessment-report_en.pdf
h1090,https://www.ema.europa.eu/documents/assessment-report/rasagiline-mylan-epar-public-assessment-report_en.pdf
h993,https://www.ema.europa.eu/documents/assessment-report/lixiana-epar-public-assessment-report_en.pdf
h1037,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-sandoz-epar-public-assessment-report_en.pdf
h1091,https://www.ema.europa.eu/documents/assessment-report/atazanavir-mylan-epar-public-assessment-report_en.pdf
h1027,https://www.ema.europa.eu/documents/assessment-report/pregabalin-accord-epar-public-assessment-report_en.pdf
h1002,https://www.ema.europa.eu/documents/assessment-report/lenvima-epar-public-assessment-report_en.pdf
h1038,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-medac-epar-public-assessment-report_en.pdf
h1028,https://www.ema.europa.eu/documents/assessment-report/duloxetine-zentiva-epar-public-assessment-report_en.pdf
h1095,https://www.ema.europa.eu/documents/assessment-report/idelvion-epar-public-assessment-report_en.pdf
h1083,https://www.ema.europa.eu/documents/assessment-report/uptravi-epar-public-assessment-report_en.pdf
h1030,https://www.ema.europa.eu/documents/assessment-report/odomzo-epar-public-assessment-report_en.pdf
h1066,https://www.ema.europa.eu/documents/assessment-report/ongentys-epar-public-assessment-report_en.pdf
h1058,https://www.ema.europa.eu/documents/assessment-report/entresto-epar-public-assessment-report_en.pdf
h1054,https://www.ema.europa.eu/documents/assessment-report/cinacalcet-mylan-epar-public-assessment-report_en.pdf
h990,https://www.ema.europa.eu/documents/assessment-report/ikervis-epar-public-assessment-report_en.pdf
h1082,https://www.ema.europa.eu/documents/assessment-report/galafold-epar-public-assessment-report_en.pdf
h1021,https://www.ema.europa.eu/documents/assessment-report/pregabalin-zentiva-epar-public-assessment-report_en.pdf
h1068,https://www.ema.europa.eu/documents/assessment-report/wakix-epar-public-assessment-report_en.pdf
h1085,https://www.ema.europa.eu/documents/assessment-report/taltz-epar-public-assessment-report_en.pdf
h1023,https://www.ema.europa.eu/documents/assessment-report/farydak-epar-public-assessment-report_en.pdf
h1070,https://www.ema.europa.eu/documents/assessment-report/oncaspar-epar-public-assessment-report_en.pdf
h1101,https://www.ema.europa.eu/documents/assessment-report/darzalex-epar-public-assessment-report_en.pdf
h1024,https://www.ema.europa.eu/documents/assessment-report/keytruda-epar-public-assessment-report_en.pdf
h1075,https://www.ema.europa.eu/documents/assessment-report/feraccru-epar-public-assessment-report_en.pdf
h1079,https://www.ema.europa.eu/documents/assessment-report/vaxelis-epar-public-assessment-report_en.pdf
h1033,https://www.ema.europa.eu/documents/assessment-report/kanuma-epar-public-assessment-report_en.pdf
h982,https://www.ema.europa.eu/documents/assessment-report/viekirax-epar-public-assessment-report_en.pdf
h1125,https://www.ema.europa.eu/documents/assessment-report/cinqaero-epar-public-assessment-report_en.pdf
h992,https://www.ema.europa.eu/documents/assessment-report/saxenda-epar-public-assessment-report_en.pdf
h983,https://www.ema.europa.eu/documents/assessment-report/exviera-epar-public-assessment-report_en.pdf
h1119,https://www.ema.europa.eu/documents/assessment-report/zepatier-epar-public-assessment-report_en.pdf
h1104,https://www.ema.europa.eu/documents/assessment-report/palonosetron-accord-epar-public-assessment-report_en.pdf
h1062,https://www.ema.europa.eu/documents/assessment-report/ravicti-epar-public-assessment-report_en.pdf
h1184,https://www.ema.europa.eu/documents/assessment-report/riximyo-epar-public-assessment-report_en.pdf
h1229,https://www.ema.europa.eu/documents/assessment-report/dupixent-epar-public-assessment-report_en.pdf
h1230,https://www.ema.europa.eu/documents/assessment-report/lacosamide-accord-epar-public-assessment-report_en.pdf
h1182,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-krka-dd-epar-public-assessment-report_en.pdf
h1124,https://www.ema.europa.eu/documents/assessment-report/nordimet-epar-public-assessment-report_en.pdf
h1146,https://www.ema.europa.eu/documents/assessment-report/glyxambi-epar-public-assessment-report_en.pdf
h1147,https://www.ema.europa.eu/documents/assessment-report/ibrance-epar-public-assessment-report_en.pdf
h1197,https://www.ema.europa.eu/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf
h1152,https://www.ema.europa.eu/documents/assessment-report/roteas-epar-public-assessment-report_en.pdf
h1141,https://www.ema.europa.eu/documents/assessment-report/somakit-toc-epar-public-assessment-report_en.pdf
h1234,https://www.ema.europa.eu/documents/assessment-report/tremfya-epar-public-assessment-report_en.pdf
h1218,https://www.ema.europa.eu/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf
h1262,https://www.ema.europa.eu/documents/assessment-report/crysvita-epar-public-assessment-report_en.pdf
h1215,https://www.ema.europa.eu/documents/assessment-report/fotivda-epar-public-assessment-report_en.pdf
h1212,https://www.ema.europa.eu/documents/assessment-report/mavenclad-epar-public-assessment-report_en.pdf
h1216,https://www.ema.europa.eu/documents/assessment-report/imraldi-epar-public-assessment-report_en.pdf
h1134,https://www.ema.europa.eu/documents/assessment-report/mysildecard-epar-public-assessment-report_en.pdf
h1222,https://www.ema.europa.eu/documents/assessment-report/efavirenz/emtricitabine/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf
h1142,https://www.ema.europa.eu/documents/assessment-report/parsabiv-epar-public-assessment-report_en.pdf
h1255,https://www.ema.europa.eu/documents/assessment-report/intrarosa-epar-public-assessment-report_en.pdf
h1016,https://www.ema.europa.eu/documents/assessment-report/repatha-epar-public-assessment-report_en.pdf
h1003,https://www.ema.europa.eu/documents/assessment-report/synjardy-epar-public-assessment-report_en.pdf
h1140,https://www.ema.europa.eu/documents/assessment-report/darunavir-mylan-epar-public-assessment-report_en.pdf
h1187,https://www.ema.europa.eu/documents/assessment-report/trumenba-epar-public-assessment-report_en.pdf
h1148,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-zentiva-epar-public-assessment-report_en.pdf
h1105,https://www.ema.europa.eu/documents/assessment-report/endolucinbeta-epar-public-assessment-report_en.pdf
h1012,https://www.ema.europa.eu/documents/assessment-report/pregabalin-sandoz-gmbh-epar-public-assessment-report_en.pdf
h1161,https://www.ema.europa.eu/documents/assessment-report/movymia-epar-public-assessment-report_en.pdf
h1074,https://www.ema.europa.eu/documents/assessment-report/benepali-epar-public-assessment-report_en.pdf
h1160,https://www.ema.europa.eu/documents/assessment-report/fiasp-epar-public-assessment-report_en.pdf
h1154,https://www.ema.europa.eu/documents/assessment-report/vemlidy-epar-public-assessment-report_en.pdf
h1151,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-krka-epar-public-assessment-report_en.pdf
h1178,https://www.ema.europa.eu/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf
h1153,https://www.ema.europa.eu/documents/assessment-report/tadalafil-generics-epar-public-assessment-report_en.pdf
h1110,https://www.ema.europa.eu/documents/assessment-report/chenodeoxycholic-acid-sigma-tau-epar-public-assessment-report_en.pdf
h1214,https://www.ema.europa.eu/documents/assessment-report/bavencio-epar-public-assessment-report_en.pdf
h1144,https://www.ema.europa.eu/documents/assessment-report/ivabradine-zentiva-epar-public-assessment-report_en.pdf
h1200,https://www.ema.europa.eu/documents/assessment-report/besponsa-epar-public-assessment-report_en.pdf
h1172,https://www.ema.europa.eu/documents/assessment-report/jylamvo-epar-public-assessment-report_en.pdf
h1116,https://www.ema.europa.eu/documents/assessment-report/epclusa-epar-public-assessment-report_en.pdf
h1193,https://www.ema.europa.eu/documents/assessment-report/refixia-epar-public-assessment-report_en.pdf
h1199,https://www.ema.europa.eu/documents/assessment-report/cuprior-epar-public-assessment-report_en.pdf
h1137,https://www.ema.europa.eu/documents/assessment-report/granpidam-epar-public-assessment-report_en.pdf
h1201,https://www.ema.europa.eu/documents/assessment-report/skilarence-epar-public-assessment-report_en.pdf
h1128,https://www.ema.europa.eu/documents/assessment-report/kisplyx-epar-public-assessment-report_en.pdf
h1223,https://www.ema.europa.eu/documents/assessment-report/vosevi-epar-public-assessment-report_en.pdf
h1195,https://www.ema.europa.eu/documents/assessment-report/erelzi-epar-public-assessment-report_en.pdf
h1265,https://www.ema.europa.eu/documents/assessment-report/segluromet-epar-public-assessment-report_en.pdf
h1228,https://www.ema.europa.eu/documents/assessment-report/tookad-epar-public-assessment-report_en.pdf
h1132,https://www.ema.europa.eu/documents/assessment-report/inhixa-epar-public-assessment-report_en.pdf
h1227,https://www.ema.europa.eu/documents/assessment-report/entecavir-mylan-epar-public-assessment-report_en.pdf
h1127,https://www.ema.europa.eu/documents/assessment-report/tenofovir-disoproxil-zentiva-epar-public-assessment-report_en.pdf
h1196,https://www.ema.europa.eu/documents/assessment-report/kevzara-epar-public-assessment-report_en.pdf
h1225,https://www.ema.europa.eu/documents/assessment-report/symtuza-epar-public-assessment-report_en.pdf
h1219,https://www.ema.europa.eu/documents/assessment-report/verkazia-epar-public-assessment-report_en.pdf
h1114,https://www.ema.europa.eu/documents/assessment-report/bortezomib-hospira-epar-public-assessment-report_en.pdf
h1267,https://www.ema.europa.eu/documents/assessment-report/steglatro-epar-public-assessment-report_en.pdf
h1236,https://www.ema.europa.eu/documents/assessment-report/trelegy-ellipta-epar-public-assessment-report_en.pdf
h1276,https://www.ema.europa.eu/documents/assessment-report/myalepta-epar-public-assessment-report_en.pdf
h1237,https://www.ema.europa.eu/documents/assessment-report/elebrato-ellipta-epar-public-assessment-report_en.pdf
h1270,https://www.ema.europa.eu/documents/assessment-report/semglee-epar-public-assessment-report_en.pdf
h1057,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-hospira-epar-public-assessment-report_en.pdf
h1221,https://www.ema.europa.eu/documents/assessment-report/kisqali-epar-public-assessment-report_en.pdf
h1238,https://www.ema.europa.eu/documents/assessment-report/nyxoid-epar-public-assessment-report_en.pdf
h1211,https://www.ema.europa.eu/documents/assessment-report/entecavir-accord-epar-public-assessment-report_en.pdf
h1175,https://www.ema.europa.eu/documents/assessment-report/daptomycin-hospira-epar-public-assessment-report_en.pdf
h1168,https://www.ema.europa.eu/documents/assessment-report/vihuma-epar-public-assessment-report_en.pdf
h1220,https://www.ema.europa.eu/documents/assessment-report/tecentriq-epar-public-assessment-report_en.pdf
h1169,https://www.ema.europa.eu/documents/assessment-report/alecensa-epar-public-assessment-report_en.pdf
h1188,https://www.ema.europa.eu/documents/assessment-report/spinraza-epar-public-assessment-report_en.pdf
h1173,https://www.ema.europa.eu/documents/assessment-report/lokelma-epar-public-assessment-report_en.pdf
h1226,https://www.ema.europa.eu/documents/assessment-report/lutathera-epar-public-assessment-report_en.pdf
h1133,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf
h1108,https://www.ema.europa.eu/documents/assessment-report/qtern-epar-public-assessment-report_en.pdf
h1155,https://www.ema.europa.eu/documents/assessment-report/kyntheum-epar-public-assessment-report_en.pdf
h1106,https://www.ema.europa.eu/documents/assessment-report/flixabi-epar-public-assessment-report_en.pdf
h1109,https://www.ema.europa.eu/documents/assessment-report/zavicefta-epar-public-assessment-report_en.pdf
h1266,https://www.ema.europa.eu/documents/assessment-report/steglujan-epar-public-assessment-report_en.pdf
h1157,https://www.ema.europa.eu/documents/assessment-report/suliqua-epar-public-assessment-report_en.pdf
h1176,https://www.ema.europa.eu/documents/assessment-report/yargesa-epar-public-assessment-report_en.pdf
h1150,https://www.ema.europa.eu/documents/assessment-report/rekovelle-epar-public-assessment-report_en.pdf
h1164,https://www.ema.europa.eu/documents/assessment-report/amgevita-epar-public-assessment-report_en.pdf
h1158,https://www.ema.europa.eu/documents/assessment-report/afstyla-epar-public-assessment-report_en.pdf
h1138,https://www.ema.europa.eu/documents/assessment-report/venclyxto-epar-public-assessment-report_en.pdf
h1194,https://www.ema.europa.eu/documents/assessment-report/febuxostat-mylan-epar-public-assessment-report_en.pdf
h1251,https://www.ema.europa.eu/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf
h1179,https://www.ema.europa.eu/documents/assessment-report/veltassa-epar-public-assessment-report_en.pdf
h1224,https://www.ema.europa.eu/documents/assessment-report/xermelo-epar-public-assessment-report_en.pdf
h1159,https://www.ema.europa.eu/documents/assessment-report/terrosa-epar-public-assessment-report_en.pdf
h1213,https://www.ema.europa.eu/documents/assessment-report/maviret-epar-public-assessment-report_en.pdf
h1129,https://www.ema.europa.eu/documents/assessment-report/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf
h1135,https://www.ema.europa.eu/documents/assessment-report/sialanar-epar-public-assessment-report_en.pdf
h1112,https://www.ema.europa.eu/documents/assessment-report/odefsey-epar-public-assessment-report_en.pdf
h1203,https://www.ema.europa.eu/documents/assessment-report/insulin-lispro-sanofi-epar-public-assessment-report_en.pdf
h1177,https://www.ema.europa.eu/documents/assessment-report/tadalafil-lilly-epar-public-assessment-report_en.pdf
h1181,https://www.ema.europa.eu/documents/assessment-report/spherox-epar-public-assessment-report_en.pdf
h1232,https://www.ema.europa.eu/documents/assessment-report/miglustat-genorph-epar-public-assessment-report_en.pdf
h1244,https://www.ema.europa.eu/documents/assessment-report/tacforius-epar-public-assessment-report_en.pdf
h1235,https://www.ema.europa.eu/documents/assessment-report/zejula-epar-public-assessment-report_en.pdf
h1202,https://www.ema.europa.eu/documents/assessment-report/ucedane-epar-public-assessment-report_en.pdf
h1166,https://www.ema.europa.eu/documents/assessment-report/pregabalin-zentiva-ks-epar-public-assessment-report_en.pdf
h1156,https://www.ema.europa.eu/documents/assessment-report/zinplava-epar-public-assessment-report_en.pdf
h1274,https://www.ema.europa.eu/documents/assessment-report/trydonis-epar-public-assessment-report_en.pdf
h1275,https://www.ema.europa.eu/documents/assessment-report/riarify-previously-chf-5993-chiesi-farmaceutici-spa-epar-public-assessment-report_en.pdf
h1170,https://www.ema.europa.eu/documents/assessment-report/olumiant-epar-public-assessment-report_en.pdf
h1239,https://www.ema.europa.eu/documents/assessment-report/veraseal-epar-public-assessment-report_en.pdf
h1246,https://www.ema.europa.eu/documents/assessment-report/mvasi-epar-public-assessment-report_en.pdf
h1205,https://www.ema.europa.eu/documents/assessment-report/blitzima-epar-public-assessment-report_en.pdf
h1258,https://www.ema.europa.eu/documents/assessment-report/lamzede-epar-public-assessment-report_en.pdf
h1261,https://www.ema.europa.eu/documents/assessment-report/alofisel-epar-public-assessment-report_en.pdf
h1250,https://www.ema.europa.eu/documents/assessment-report/rubraca-epar-public-assessment-report_en.pdf
h1190,https://www.ema.europa.eu/documents/assessment-report/ivabradine-accord-epar-public-assessment-report_en.pdf
h1245,https://www.ema.europa.eu/documents/assessment-report/prevymis-epar-public-assessment-report_en.pdf
h1254,https://www.ema.europa.eu/documents/assessment-report/jorveza-epar-public-assessment-report_en.pdf
h1089,https://www.ema.europa.eu/documents/assessment-report/pandemic-influenza-vaccine-h5n1-medimmune-epar-public-assessment-report_en.pdf
h1260,https://www.ema.europa.eu/documents/assessment-report/alkindi-epar-public-assessment-report_en.pdf
h1231,https://www.ema.europa.eu/documents/assessment-report/ocrevus-epar-public-assessment-report_en.pdf
h1171,https://www.ema.europa.eu/documents/assessment-report/ledaga-epar-public-assessment-report_en.pdf
h1264,https://www.ema.europa.eu/documents/assessment-report/alunbrig-epar-public-assessment-report_en.pdf
h1233,https://www.ema.europa.eu/documents/assessment-report/zubsolv-epar-public-assessment-report_en.pdf
h1242,https://www.ema.europa.eu/documents/assessment-report/ritonavir-mylan-epar-public-assessment-report_en.pdf
h1241,https://www.ema.europa.eu/documents/assessment-report/ontruzant-epar-public-assessment-report_en-0.pdf
h1253,https://www.ema.europa.eu/documents/assessment-report/fulvestrant-mylan-epar-public-assessment-report_en.pdf
h1185,https://www.ema.europa.eu/documents/assessment-report/rixathon-epar-public-assessment-report_en.pdf
h1208,https://www.ema.europa.eu/documents/assessment-report/trimbow-epar-public-assessment-report_en.pdf
h1272,https://www.ema.europa.eu/documents/assessment-report/shingrix-epar-public-assessment-report_en.pdf
h1186,https://www.ema.europa.eu/documents/assessment-report/axumin-epar-public-assessment-report_en.pdf
h1263,https://www.ema.europa.eu/documents/assessment-report/efavirenz/emtricitabine/tenofovir-disoproxil-krka-epar-public-assessment-report_en.pdf
h1271,https://www.ema.europa.eu/documents/assessment-report/hemlibra-epar-public-assessment-report_en.pdf
h1209,https://www.ema.europa.eu/documents/assessment-report/reagila-epar-public-assessment-report_en.pdf
h1004,https://www.ema.europa.eu/documents/assessment-report/voriconazole-hospira-epar-public-assessment-report_en.pdf
h1269,https://www.ema.europa.eu/documents/assessment-report/alpivab-epar-public-assessment-report_en.pdf
h1167,https://www.ema.europa.eu/documents/assessment-report/truxima-epar-public-assessment-report_en.pdf
h1279,https://www.ema.europa.eu/documents/assessment-report/amglidia-epar-public-assessment-report_en.pdf
h1217,https://www.ema.europa.eu/documents/assessment-report/nitisinone-mendelikabs-epar-public-assessment-report_en.pdf
h1282,https://www.ema.europa.eu/documents/assessment-report/juluca-epar-public-assessment-report_en.pdf
h1136,https://www.ema.europa.eu/documents/assessment-report/cabometyx-epar-public-assessment-report_en.pdf
h1252,https://www.ema.europa.eu/documents/assessment-report/fasenra-epar-public-assessment-report_en.pdf
h1281,https://www.ema.europa.eu/documents/assessment-report/kanjinti-epar-public-assessment-report_en.pdf
h1410,https://www.ema.europa.eu/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf
h1192,https://www.ema.europa.eu/documents/assessment-report/brineura-epar-public-assessment-report_en.pdf
h1278,https://www.ema.europa.eu/documents/assessment-report/carmustine-obvius-epar-public-assessment-report_en.pdf
h1247,https://www.ema.europa.eu/documents/assessment-report/adynovi-epar-public-assessment-report_en.pdf
h1280,https://www.ema.europa.eu/documents/assessment-report/zessly-epar-public-assessment-report_en.pdf
h1393,https://www.ema.europa.eu/documents/assessment-report/quofenix-epar-public-assessment-report_en.pdf
h1283,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-krka-epar-public-assessment-report_en.pdf
h1396,https://www.ema.europa.eu/documents/assessment-report/ivozall-epar-public-assessment-report_en.pdf
h1459,https://www.ema.europa.eu/documents/assessment-report/veklury-epar-public-assessment-report_en.pdf
h1392,https://www.ema.europa.eu/documents/assessment-report/ervebo-epar-public-assessment-report_en.pdf
h1447,https://www.ema.europa.eu/documents/assessment-report/insulin-aspart-sanofi-epar-public-assessment-report_en.pdf
h1460,https://www.ema.europa.eu/documents/assessment-report/rozlytrek-epar-public-assessment-report_en.pdf
h1397,https://www.ema.europa.eu/documents/assessment-report/bortezomib-fresenius-kabi-epar-public-assessment-report_en.pdf
h1474,https://www.ema.europa.eu/documents/assessment-report/blenrep-epar-public-assessment-report_en-0.pdf
h1371,https://www.ema.europa.eu/documents/assessment-report/ultomiris-epar-public-assessment-report_en.pdf
h1372,https://www.ema.europa.eu/documents/assessment-report/striascan-epar-public-assessment-report_en.pdf
h1375,https://www.ema.europa.eu/documents/assessment-report/grasustek-epar-public-assessment-report_en.pdf
h1476,https://www.ema.europa.eu/documents/assessment-report/adakveo-epar-public-assessment-report_en.pdf
h1374,https://www.ema.europa.eu/documents/assessment-report/esperoct-epar-public-assessment-report_en.pdf
h1365,https://www.ema.europa.eu/documents/assessment-report/cufence-epar-public-assessment-report_en.pdf
h1376,https://www.ema.europa.eu/documents/assessment-report/libtayo-epar-public-assessment-report_en.pdf
h1370,https://www.ema.europa.eu/documents/assessment-report/dovato-epar-public-assessment-report_en.pdf
h1334,https://www.ema.europa.eu/documents/assessment-report/vabomere-epar-public-assessment-report_en.pdf
h1249,https://www.ema.europa.eu/documents/assessment-report/darunavir-krka-epar-public-assessment-report_en.pdf
h1115,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-fresenius-kabi-epar-public-assessment-report_en.pdf
h1356,https://www.ema.europa.eu/documents/assessment-report/idacio-epar-public-assessment-report_en.pdf
h1174,https://www.ema.europa.eu/documents/assessment-report/rolufta-epar-public-assessment-report_en.pdf
h1455,https://www.ema.europa.eu/documents/assessment-report/piqray-epar-public-assessment-report_en.pdf
h1454,https://www.ema.europa.eu/documents/assessment-report/aybintio-epar-public-assessment-report_en.pdf
h1377,https://www.ema.europa.eu/documents/assessment-report/talzenna-epar-public-assessment-report_en.pdf
h1364,https://www.ema.europa.eu/documents/assessment-report/nuceiva-epar-public-assessment-report_en.pdf
h1408,https://www.ema.europa.eu/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
h1456,https://www.ema.europa.eu/documents/assessment-report/zercepac-epar-public-assessment-report_en.pdf
h1471,https://www.ema.europa.eu/documents/assessment-report/idefirix-epar-public-assessment-report_en.pdf
h1473,https://www.ema.europa.eu/documents/assessment-report/ayvakyt-epar-public-assessment-report_en.pdf
h1256,https://www.ema.europa.eu/documents/assessment-report/anagrelide-mylan-epar-public-assessment-report_en.pdf
h1277,https://www.ema.europa.eu/documents/assessment-report/mylotarg-epar-public-assessment-report_en.pdf
h1210,https://www.ema.europa.eu/documents/assessment-report/efavirenz/emtricitabine/tenofovir-disoproxil-zentiva-epar-public-assessment-report_en.pdf
h1411,https://www.ema.europa.eu/documents/assessment-report/evenity-epar-public-assessment-report_en.pdf
h1405,https://www.ema.europa.eu/documents/assessment-report/tavlesse-epar-public-assessment-report_en.pdf
h1465,https://www.ema.europa.eu/documents/assessment-report/gencebok-epar-public-assessment-report_en.pdf
h1400,https://www.ema.europa.eu/documents/assessment-report/rhokiinsa-epar-public-assessment-report_en.pdf
h1362,https://www.ema.europa.eu/documents/assessment-report/palynziq-epar-public-assessment-report_en.pdf
h1404,https://www.ema.europa.eu/documents/assessment-report/rinvoq-epar-public-assessment-report_en.pdf
h1452,https://www.ema.europa.eu/documents/assessment-report/reblozyl-epar-public-assessment-report_en.pdf
h1468,https://www.ema.europa.eu/documents/assessment-report/kaftrio-epar-public-assessment-report_en.pdf
h1406,https://www.ema.europa.eu/documents/assessment-report/baqsimi-epar-public-assessment-report_en.pdf
h1366,https://www.ema.europa.eu/documents/assessment-report/xromi-epar-public-assessment-report_en.pdf
h1480,https://www.ema.europa.eu/documents/assessment-report/jyseleca-epar-public-assessment-report_en.pdf
h1292,https://www.ema.europa.eu/documents/assessment-report/apealea-epar-public-assessment-report_en.pdf
h1475,https://www.ema.europa.eu/documents/assessment-report/arsenic-trioxide-medac-epar-public-assessment-report_en.pdf
h1398,https://www.ema.europa.eu/documents/assessment-report/arsenic-trioxide-accord-epar-public-assessment-report_en.pdf
h1409,https://www.ema.europa.eu/documents/assessment-report/pegfilgrastim-mundipharma-epar-public-assessment-report_en.pdf
h1385,https://www.ema.europa.eu/documents/assessment-report/vitrakvi-epar-public-assessment-report_en.pdf
h1361,https://www.ema.europa.eu/documents/assessment-report/skyrizi-epar-public-assessment-report_en.pdf
h1395,https://www.ema.europa.eu/documents/assessment-report/clopidogrel/acetylsalicylic-acid-mylan-epar-public-assessment-report_en.pdf
h1386,https://www.ema.europa.eu/documents/assessment-report/deferasirox-mylan-epar-public-assessment-report_en.pdf
h1540,https://www.ema.europa.eu/documents/assessment-report/dasatinib-accord-epar-public-assessment-report_en.pdf
h1448,https://www.ema.europa.eu/documents/assessment-report/cabazitaxel-accord-epar-public-assessment-report_en.pdf
h1541,https://www.ema.europa.eu/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf
h1284,https://www.ema.europa.eu/documents/assessment-report/dzuveo-epar-public-assessment-report_en.pdf
h1389,https://www.ema.europa.eu/documents/assessment-report/epidyolex-epar-public-assessment-report_en.pdf
h1469,https://www.ema.europa.eu/documents/assessment-report/arikayce-liposomal-epar-public-assessment-report_en.pdf
h1450,https://www.ema.europa.eu/documents/assessment-report/fingolimod-accord-epar-public-assessment-report_en.pdf
h001,https://www.ema.europa.eu/documents/scientific-discussion/gonal-f-epar-scientific-discussion_en.pdf
h1302,https://www.ema.europa.eu/documents/assessment-report/kigabeq-epar-public-assessment-report_en.pdf
h1539,https://www.ema.europa.eu/documents/assessment-report/abecma-epar-public-assessment-report_en.pdf
h1360,https://www.ema.europa.eu/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf
h1358,https://www.ema.europa.eu/documents/assessment-report/ajovy-epar-public-assessment-report_en.pdf
h1387,https://www.ema.europa.eu/documents/assessment-report/senstend-epar-public-assessment-report_en.pdf
h1290,https://www.ema.europa.eu/documents/assessment-report/nityr-epar-public-assessment-report_en.pdf
h1388,https://www.ema.europa.eu/documents/assessment-report/polivy-epar-public-assessment-report_en.pdf
h1296,https://www.ema.europa.eu/documents/assessment-report/tegsedi-epar-public-assessment-report_en.pdf
h1354,https://www.ema.europa.eu/documents/assessment-report/vizimpro-epar-public-assessment-report_en.pdf
h1297,https://www.ema.europa.eu/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf
h1353,https://www.ema.europa.eu/documents/assessment-report/atazanavir-krka-epar-public-assessment-report_en.pdf
h1479,https://www.ema.europa.eu/documents/assessment-report/calquence-epar-public-assessment-report_en.pdf
h1359,https://www.ema.europa.eu/documents/assessment-report/trogarzo-epar-public-assessment-report_en.pdf
h1294,https://www.ema.europa.eu/documents/assessment-report/rxulti-epar-public-assessment-report_en.pdf
h1355,https://www.ema.europa.eu/documents/assessment-report/lorviqua-epar-public-assessment-report_en.pdf
h1477,https://www.ema.europa.eu/documents/assessment-report/fampridine-accord-epar-public-assessment-report_en.pdf
h1289,https://www.ema.europa.eu/documents/assessment-report/biktarvy-epar-public-assessment-report_en.pdf
h1299,https://www.ema.europa.eu/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf
h1399,https://www.ema.europa.eu/documents/assessment-report/xospata-epar-public-assessment-report_en.pdf
h1407,https://www.ema.europa.eu/documents/assessment-report/isturisa-epar-public-assessment-report_.pdf
h1368,https://www.ema.europa.eu/documents/assessment-report/ambrisentan-mylan-epar-public-assessment-report_en.pdf
h1462,https://www.ema.europa.eu/documents/assessment-report/livogiva-epar-public-assessment-report_en.pdf
h1451,https://www.ema.europa.eu/documents/assessment-report/daurismo-epar-public-assessment-report_en.pdf
h1369,https://www.ema.europa.eu/documents/assessment-report/sixmo-epar-public-assessment-report_en.pdf
h1457,https://www.ema.europa.eu/documents/assessment-report/xenleta-epar-public-assessment-report_en.pdf
h1287,https://www.ema.europa.eu/documents/assessment-report/hefiya-epar-public-assessment-report_en.pdf
h1458,https://www.ema.europa.eu/documents/assessment-report/apixaban-accord-epar-public-assessment-report_en.pdf
h1351,https://www.ema.europa.eu/documents/assessment-report/trecondi-epar-public-assessment-report_en.pdf
h1330,https://www.ema.europa.eu/documents/assessment-report/emgality-h-c-04648-x-0004-epar-refusal-public-assessment-report_en.pdf
h1403,https://www.ema.europa.eu/documents/assessment-report/budesonide/formoterol-teva-pharma-bv-epar-public-assessment-report_en.pdf
h1478,https://www.ema.europa.eu/documents/assessment-report/zynrelef-epar-public-assessment-report_en.pdf
h1352,https://www.ema.europa.eu/documents/assessment-report/besremi-epar-public-assessment-report_en.pdf
h1329,https://www.ema.europa.eu/documents/assessment-report/fulphila-public-assessment-report_en.pdf
h1328,https://www.ema.europa.eu/documents/assessment-report/pelmeg-epar-public-assessment-report_en.pdf
h1535,https://www.ema.europa.eu/documents/assessment-report/pemazyre-epar-public-assessment-report_en.pdf
h1492,https://www.ema.europa.eu/documents/assessment-report/tecartus-epar-public-assessment-report_en.pdf
h1536,https://www.ema.europa.eu/documents/assessment-report/thiotepa-riemser-epar-public-assessment-report_en.pdf
h1493,https://www.ema.europa.eu/documents/assessment-report/libmeldy-epar-public-assessment-report_en.pdf
h1442,https://www.ema.europa.eu/documents/assessment-report/zeposia-epar-public-assessment-report_en.pdf
h1417,https://www.ema.europa.eu/documents/assessment-report/beovu-epar-public-assessment-report_en.pdf
h1348,https://www.ema.europa.eu/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf
h1324,https://www.ema.europa.eu/documents/assessment-report/jivi-public-assessment-report_en.pdf
h1312,https://www.ema.europa.eu/documents/assessment-report/xerava-epar-public-assessment-report_en.pdf
h1321,https://www.ema.europa.eu/documents/assessment-report/gefitinib-mylan-epar-public-assessment-report_en.pdf
h1418,https://www.ema.europa.eu/documents/assessment-report/dexmedetomidine-accord-epar-public-assessment-report_en.pdf
h1344,https://www.ema.europa.eu/documents/assessment-report/zirabev-epar-public-assessment-report_en.pdf
h1345,https://www.ema.europa.eu/documents/assessment-report/ondexxya-epar-public-assessment-report_en.pdf
h1496,https://www.ema.europa.eu/documents/assessment-report/oxlumo-epar-public-assessment-report_en.pdf
h1518,https://www.ema.europa.eu/documents/assessment-report/rukobia-epar-public-assessment-report_en.pdf
h1318,https://www.ema.europa.eu/documents/assessment-report/slenyto-epar-public-assessment-report_en.pdf
h1313,https://www.ema.europa.eu/documents/assessment-report/pelgraz-epar-public-assessment-report_en.pdf
h1499,https://www.ema.europa.eu/documents/assessment-report/onbevzi-epar-public-assessment-report_en.pdf
h1331,https://www.ema.europa.eu/documents/assessment-report/luxturna-epar-public-assessment-report_en.pdf
h1333,https://www.ema.europa.eu/documents/assessment-report/delstrigo-epar-public-assessment-report_en.pdf
h1373,https://www.ema.europa.eu/documents/assessment-report/doptelet-epar-public-assessment-report_en.pdf
h1332,https://www.ema.europa.eu/documents/assessment-report/pifeltro-epar-public-assessment-report_en.pdf
h1425,https://www.ema.europa.eu/documents/assessment-report/nilemdo-epar-public-assessment-report_en.pdf
h1325,https://www.ema.europa.eu/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf
h1326,https://www.ema.europa.eu/documents/assessment-report/flucelvax-tetra-epar-public-assessment-report_en.pdf
h1380,https://www.ema.europa.eu/documents/assessment-report/posaconazole-ahcl-epar-public-assessment-report_en.pdf
h1482,https://www.ema.europa.eu/documents/assessment-report/rekambys-epar-public-assessment-report_en.pdf
h1340,https://www.ema.europa.eu/documents/assessment-report/takhzyro-epar-public-assessment-report_en.pdf
h1424,https://www.ema.europa.eu/documents/assessment-report/nustendi-epar-public-assessment-report_en.pdf
h1538,https://www.ema.europa.eu/documents/assessment-report/jemperli-epar-public-assessment-report_en.pdf
h1311,https://www.ema.europa.eu/documents/assessment-report/nerlynx-epar-public-assessment-report_en.pdf
h1349,https://www.ema.europa.eu/documents/assessment-report/dectova-epar-public-assessment-report_en.pdf
h1306,https://www.ema.europa.eu/documents/assessment-report/symkevi-epar-public-assessment-report_en.pdf
h1130,https://www.ema.europa.eu/documents/assessment-report/onivyde-epar-public-assessment-report_en.pdf
h1515,https://www.ema.europa.eu/documents/assessment-report/abevmy-epar-public-assessment-report_en.pdf
h1426,https://www.ema.europa.eu/documents/assessment-report/azacitidine-mylan-epar-public-assessment-report_en.pdf
h1486,https://www.ema.europa.eu/documents/assessment-report/nyvepria-epar-public-assessment-report_en.pdf
h1527,https://www.ema.europa.eu/documents/assessment-report/retsevmo-epar-public-assessment-report_en.pdf
h1490,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-mylan-epar-public-assessment-report_en.pdf
h1293,https://www.ema.europa.eu/documents/assessment-report/aimovig-epar-public-assessment-report_en.pdf
h1412,https://www.ema.europa.eu/documents/assessment-report/deferasirox-accord-epar-public-assessment-report_en.pdf
h011,https://www.ema.europa.eu/documents/scientific-discussion/caelyx-epar-scientific-discussion_en.pdf
h1307,https://www.ema.europa.eu/documents/assessment-report/verzenios-epar-public-assessment-report_en.pdf
h922,https://www.ema.europa.eu/documents/assessment-report/incruse-epar-public-assessment-report_en.pdf
h1487,https://www.ema.europa.eu/documents/assessment-report/phelinun-epar-public-assessment-report_en.pdf
h1341,https://www.ema.europa.eu/documents/assessment-report/ogivri-epar-public-assessment-report_en.pdf
h898,https://www.ema.europa.eu/documents/assessment-report/anoro-epar-public-assessment-report_en.pdf
h1495,https://www.ema.europa.eu/documents/assessment-report/palforzia-epar-public-assessment-report_en.pdf
h1524,https://www.ema.europa.eu/documents/assessment-report/vazkepa-epar-public-assessment-report_en.pdf
h1295,https://www.ema.europa.eu/documents/assessment-report/trazimera-epar-public-assessment-report_en.pdf
h1497,https://www.ema.europa.eu/documents/assessment-report/phesgo-epar-public-assessment-report_en.pdf
h1501,https://www.ema.europa.eu/documents/assessment-report/sogroya-epar-public-assessment-report_en.pdf
h1319,https://www.ema.europa.eu/documents/assessment-report/hulio-epar-public-assessment-report_en.pdf
h1413,https://www.ema.europa.eu/documents/assessment-report/azacitidine-accord-epar-public-assessment-report_en.pdf
h1191,https://www.ema.europa.eu/documents/assessment-report/dinutuximab-beta-apeiron-epar-public-assessment-report_en.pdf
h1416,https://www.ema.europa.eu/documents/assessment-report/azacitidine-betapharm-epar-public-assessment-report_.pdf
h1533,https://www.ema.europa.eu/documents/assessment-report/seffalair-spiromax-epar-public-assessment-report_en.pdf
h1437,https://www.ema.europa.eu/documents/assessment-report/pretomanid-fgk-epar-public-assessment-report_en.pdf
h1534,https://www.ema.europa.eu/documents/assessment-report/bropair-spiromax-epar-public-assessment-report_en.pdf
h1315,https://www.ema.europa.eu/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf
h1314,https://www.ema.europa.eu/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf
h1488,https://www.ema.europa.eu/documents/assessment-report/rivaroxaban-accord-epar-public-assessment-report_en.pdf
h1537,https://www.ema.europa.eu/documents/assessment-report/nexpovio-epar-public-assessment-report_en.pdf
h1338,https://www.ema.europa.eu/documents/assessment-report/dengvaxia-epar-public-assessment-report_en.pdf
h1342,https://www.ema.europa.eu/documents/assessment-report/erleada-epar-public-assessment-report_en.pdf
h1526,https://www.ema.europa.eu/documents/assessment-report/tukysa-epar-public-assessment-report_en.pdf
h1381,https://www.ema.europa.eu/documents/assessment-report/lysakare-epar-public-assessment-report_en.pdf
h1316,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-accord-epar-public-assessment-report_en.pdf
h1441,https://www.ema.europa.eu/documents/assessment-report/bemrist-breezhaler-epar-public-assessment-report_en.pdf
h204,https://www.ema.europa.eu/documents/scientific-discussion/trisenox-epar-scientific-discussion_en.pdf
h1383,https://www.ema.europa.eu/documents/assessment-report/lacosamide-ucb-epar-public-assessment-report_en.pdf
h1310,https://www.ema.europa.eu/documents/assessment-report/deferiprone-lipomed-epar-public-assessment-report_en.pdf
h1439,https://www.ema.europa.eu/documents/assessment-report/atectura-breezhaler-epar-public-assessment-report_en.pdf
h1423,https://www.ema.europa.eu/documents/assessment-report/vaxchora-epar-public-assessment-report_en.pdf
h1438,https://www.ema.europa.eu/documents/assessment-report/enerzair-breezhaler-epar-public-assessment-report_en.pdf
h1343,https://www.ema.europa.eu/documents/assessment-report/silodosin-recordati-epar-public-assessment-report_en.pdf
h1419,https://www.ema.europa.eu/documents/assessment-report/trepulmix-epar-public-assessment-report_en.pdf
h1440,https://www.ema.europa.eu/documents/assessment-report/zimbus-breezhaler-epar-public-assessment-report_en.pdf
h1517,https://www.ema.europa.eu/documents/assessment-report/sibnayal-epar-public-assessment-report_en.pdf
h1320,https://www.ema.europa.eu/documents/assessment-report/onpattro-epar-public-assessment-report_.pdf
h1429,https://www.ema.europa.eu/documents/assessment-report/cinacalcet-accordpharma-epar-public-assessment-report_en.pdf
h1430,https://www.ema.europa.eu/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf
h1503,https://www.ema.europa.eu/documents/assessment-report/heplisav-b-epar-public-assessment-report_en.pdf
h1433,https://www.ema.europa.eu/documents/assessment-report/fluad-tetra-epar-public-assessment-report_en.pdf
h1335,https://www.ema.europa.eu/documents/assessment-report/poteligeo-epar-public-assessment-report_en.pdf
h1504,https://www.ema.europa.eu/documents/assessment-report/elzonris-epar-public-assessment-report_en.pdf
h1498,https://www.ema.europa.eu/documents/assessment-report/trixeo-aerosphere-epar-public-assessment-report_en.pdf
h1528,https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
h1286,https://www.ema.europa.eu/documents/assessment-report/hyrimoz-epar-public-assessment-report_en.pdf
h1446,https://www.ema.europa.eu/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf
h1427,https://www.ema.europa.eu/documents/assessment-report/arsenic-trioxide-mylan-epar-public-assessment-report_en.pdf
h1435,https://www.ema.europa.eu/documents/assessment-report/sarclisa-epar-public-assessment-report_en-0.pdf
h1139,https://www.ema.europa.eu/documents/assessment-report/ocaliva-epar-public-assessment-report_en.pdf
h1502,https://www.ema.europa.eu/documents/assessment-report/roclanda-epar-public-assessment-report_en.pdf
h1322,https://www.ema.europa.eu/documents/assessment-report/imfinzi-epar-public-assessment-report_en.pdf
h1505,https://www.ema.europa.eu/documents/assessment-report/byfavo-epar-public-assessment-report_en.pdf
h1509,https://www.ema.europa.eu/documents/assessment-report/alymsys-epar-public-assessment-report_en.pdf
h1511,https://www.ema.europa.eu/documents/assessment-report/sunitinib-accord-epar-public-assessment-report_en.pdf
h1510,https://www.ema.europa.eu/documents/assessment-report/oyavas-epar-public-assessment-report_en.pdf
h1339,https://www.ema.europa.eu/documents/assessment-report/bevespi-aerosphere-epar-public-assessment-report_en.pdf
h1512,https://www.ema.europa.eu/documents/assessment-report/abiraterone-accord-epar-public-assessment-report_en.pdf
h1421,https://www.ema.europa.eu/documents/assessment-report/staquis-epar-public-assessment-report_en.pdf
h1422,https://www.ema.europa.eu/documents/assessment-report/liumjev-epar-public-assessment-report_en.pdf
h141,https://www.ema.europa.eu/documents/scientific-discussion/myocet-epar-scientific-discussion_en.pdf
h1489,https://www.ema.europa.eu/documents/assessment-report/exparel-liposomal-epar-public-assessment-report_en.pdf
h1530,https://www.ema.europa.eu/documents/assessment-report/ontozry-epar-public-assessment-report_.pdf
h1384,https://www.ema.europa.eu/documents/assessment-report/giapreza-epar-public-assessment-report_en.pdf
h1327,https://www.ema.europa.eu/documents/assessment-report/ziextenzo-epar-public-assessment-report_en.pdf
h1346,https://www.ema.europa.eu/documents/assessment-report/miglustat-dipharma-epar-public-assessment-report_en.pdf
h1523,https://www.ema.europa.eu/documents/assessment-report/ogluo-epar-public-assessment-report_en.pdf
h1436,https://www.ema.europa.eu/documents/assessment-report/nepexto-epar-public-assessment-report_en.pdf
h1301,https://www.ema.europa.eu/documents/assessment-report/mepsevii-epar-public-assessment-report_en.pdf
h1491,https://www.ema.europa.eu/documents/assessment-report/fintepla-epar-public-assessment-report_en.pdf
h1513,https://www.ema.europa.eu/documents/assessment-report/yuflyma-epar-public-assessment-report_en.pdf
h1414,https://www.ema.europa.eu/documents/assessment-report/mayzent-epar-public-assessment-report_en.pdf
h1317,https://www.ema.europa.eu/documents/assessment-report/pazenir-epar-public-assessment-report_en.pdf
h1514,https://www.ema.europa.eu/documents/assessment-report/inrebic-epar-public-assessment-report_en.pdf
h1305,https://www.ema.europa.eu/documents/assessment-report/cablivi-epar-public-assessment-report_en.pdf
h1483,https://www.ema.europa.eu/documents/assessment-report/menquadfi-epar-public-assessment-report_en.pdf
h1415,https://www.ema.europa.eu/documents/assessment-report/amsparity-epar-public-assessment-report_en.pdf
h1347,https://www.ema.europa.eu/documents/assessment-report/febuxostat-krka-epar-public-assessment-report_en.pdf
h1484,https://www.ema.europa.eu/documents/assessment-report/supemtek-epar-public-assessment-report_en.pdf
h1500,https://www.ema.europa.eu/documents/assessment-report/xofluza-epar-public-assessment-report_en.pdf
h1531,https://www.ema.europa.eu/documents/assessment-report/evrysdi-epar-public-assessment-report_en.pdf
h1485,https://www.ema.europa.eu/documents/assessment-report/obiltoxaximab-sfl-epar-public-assessment-report_en.pdf
h1428,https://www.ema.europa.eu/documents/assessment-report/givlaari-epar-public-assessment-report_en.pdf
h1532,https://www.ema.europa.eu/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf
h1481,https://www.ema.europa.eu/documents/assessment-report/vocabria-epar-public-assessment-report_en.pdf
h1420,https://www.ema.europa.eu/documents/assessment-report/recarbrio-epar-public-assessment-report_en.pdf
h1432,https://www.ema.europa.eu/documents/assessment-report/nubeqa-epar-public-assessment-report_en.pdf
h1508,https://www.ema.europa.eu/documents/assessment-report/enhertu-epar-public-assessment-report_en.pdf
h696,https://www.ema.europa.eu/documents/assessment-report/bydureon-epar-public-assessment-report_en.pdf
h1308,https://www.ema.europa.eu/documents/assessment-report/vyxeos-epar-public-assessment-report_en.pdf
h1445,https://www.ema.europa.eu/documents/assessment-report/mvabea-epar-public-assessment-report_en.pdf
h1494,https://www.ema.europa.eu/documents/assessment-report/leqvio-epar-public-assessment-report_en.pdf
h1431,https://www.ema.europa.eu/documents/assessment-report/ruxience-epar-public-assessment-report_en.pdf
h1323,https://www.ema.europa.eu/documents/assessment-report/ilumetri-epar-public-assessment-report_en.pdf
h1443,https://www.ema.europa.eu/documents/assessment-report/zolgensma-epar-public-assessment-report_en.pdf
h1291,https://www.ema.europa.eu/documents/assessment-report/rizmoic-epar-public-assessment-report_en.pdf
h1589,https://www.ema.europa.eu/documents/assessment-report/hukyndra-epar-public-assessment-report_en.pdf
h1590,https://www.ema.europa.eu/documents/assessment-report/libmyris-epar-public-assessment-report_en.pdf
h1644,https://www.ema.europa.eu/documents/assessment-report/inpremzia-epar-public-assessment-report_en.pdf
h1588,https://www.ema.europa.eu/documents/assessment-report/rivaroxaban-mylan-epar-public-assessment-report_en.pdf
h1561,https://www.ema.europa.eu/documents/assessment-report/verquvo-epar-public-assessment-report_en.pdf
h1597,https://www.ema.europa.eu/documents/assessment-report/regkirona-epar-public-assessment-report_en.pdf
h1598,https://www.ema.europa.eu/documents/assessment-report/sitagliptin-sun-epar-public-assessment-report_en.pdf
h1612,https://www.ema.europa.eu/documents/assessment-report/apexxnar-epar-public-assessment-report_en.pdf
h443,https://www.ema.europa.eu/documents/assessment-report/thalidomide-celgene-epar-public-assessment-report_en.pdf
h1519,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-krka-dd-novo-mesto-epar-public-assessment-report_en.pdf
h1548,https://www.ema.europa.eu/documents/assessment-report/lydisilka-epar-public-assessment-report_en.pdf
h1547,https://www.ema.europa.eu/documents/assessment-report/drovelis-epar-public-assessment-report_en.pdf
h1542,https://www.ema.europa.eu/documents/assessment-report/copiktra-epar-public-assessment-report_en.pdf
h1600,https://www.ema.europa.eu/documents/assessment-report/tecovirimat-siga-epar-public-assessment-report_en.pdf
h1594,https://www.ema.europa.eu/documents/assessment-report/rybrevant-epar-public-assessment-report_en.pdf
h1520,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-krka-epar-public-assessment-report_en.pdf
h1608,https://www.ema.europa.eu/documents/assessment-report/wegovy-epar-public-assessment-report_en.pdf
h1550,https://www.ema.europa.eu/documents/assessment-report/ponvory-epar-public-assessment-report_en.pdf
h1596,https://www.ema.europa.eu/documents/assessment-report/tepmetko-epar-public-assessment-report_en.pdf
h1546,https://www.ema.europa.eu/documents/assessment-report/ozawade-epar-public-assessment-report_en.pdf
h1555,https://www.ema.europa.eu/documents/assessment-report/gavreto-epar-public-assessment-report_en.pdf
h1470,https://www.ema.europa.eu/documents/assessment-report/methylthioninium-chloride-cosmo-epar-public-assessment-report_en.pdf
h1556,https://www.ema.europa.eu/documents/assessment-report/onureg-epar-public-assessment-report_en.pdf
h1576,https://www.ema.europa.eu/documents/assessment-report/brukinsa-epar-public-assessment-report_en.pdf
h1601,https://www.ema.europa.eu/documents/assessment-report/ronapreve-epar-public-assessment-report_en.pdf
h1593,https://www.ema.europa.eu/documents/assessment-report/cibinqo-epar-public-assessment-report_en.pdf
h271,https://www.ema.europa.eu/documents/scientific-discussion/advate-epar-scientific-discussion_en.pdf
h1602,https://www.ema.europa.eu/documents/assessment-report/uplizna-epar-public-assessment-report_en.pdf
h1635,https://www.ema.europa.eu/documents/assessment-report/dimethyl-fumarate-polpharma-epar-public-assessment-report_en.pdf
h1607,https://www.ema.europa.eu/documents/assessment-report/lonapegsomatropin-ascendis-pharma-epar-public-assessment-report_en.pdf
h1434,https://www.ema.europa.eu/documents/assessment-report/fetcroja-epar-public-assessment-report_en.pdf
h1638,https://www.ema.europa.eu/documents/assessment-report/quviviq-epar-public-assessment-report_en.pdf
h1645,https://www.ema.europa.eu/documents/assessment-report/vydura-epar-public-assessment-report_en.pdf
h1553,https://www.ema.europa.eu/documents/assessment-report/abiraterone-krka-epar-public-assessment-report_en.pdf
h1637,https://www.ema.europa.eu/documents/assessment-report/dimethyl-fumarate-neuraxpharm-epar-public-assessment-report_en.pdf
h1605,https://www.ema.europa.eu/documents/assessment-report/tavneos-epar-public-assessment-report_en.pdf
h1591,https://www.ema.europa.eu/documents/assessment-report/vaxneuvance-epar-public-assessment-report_en.pdf
h1606,https://www.ema.europa.eu/documents/assessment-report/yselty-epar-public-assessment-report_en.pdf
h1189,https://www.ema.europa.eu/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf
h1569,https://www.ema.europa.eu/documents/assessment-report/qinlock-epar-public-assessment-report_en.pdf
h1616,https://www.ema.europa.eu/documents/assessment-report/kerendia-epar-public-assessment-report_en.pdf
h1663,https://www.ema.europa.eu/documents/assessment-report/sugammadex-fresenius-kabi-epar-public-assessment-report_en.pdf
h1617,https://www.ema.europa.eu/documents/assessment-report/ngenla-epar-public-assessment-report_en.pdf
h1568,https://www.ema.europa.eu/documents/assessment-report/imatinib-koanaa-epar-public-assessment-report_en.pdf
h1337,https://www.ema.europa.eu/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf
h1634,https://www.ema.europa.eu/documents/assessment-report/dimethyl-fumarate-mylan-epar-public-assessment-report_en.pdf
h1615,https://www.ema.europa.eu/documents/assessment-report/padcev-epar-public-assessment-report_en.pdf
h1599,https://www.ema.europa.eu/documents/assessment-report/vyepti-epar-public-assessment-report_en.pdf
h1552,https://www.ema.europa.eu/documents/assessment-report/koselugo-epar-public-assessment-report_en.pdf
h1622,https://www.ema.europa.eu/documents/assessment-report/oxbryta-epar-public-assessment-report_en.pdf
h1572,https://www.ema.europa.eu/documents/assessment-report/byooviz-epar-public-assessment-report_en.pdf
h1574,https://www.ema.europa.eu/documents/assessment-report/evrenzo-epar-public-assessment-report_en.pdf
h1639,https://www.ema.europa.eu/documents/assessment-report/truvelog-mix-30-epar-public-assessment-report_en.pdf
h1633,https://www.ema.europa.eu/documents/assessment-report/sitagliptin-accord-epar-public-assessment-report_en.pdf
h1577,https://www.ema.europa.eu/documents/assessment-report/voxzogo-epar-public-assessment-report_en.pdf
h1603,https://www.ema.europa.eu/documents/assessment-report/lumykras-epar-public-assessment-report_en.pdf
h1624,https://www.ema.europa.eu/documents/assessment-report/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-public-assessment-report_en.pdf
h1640,https://www.ema.europa.eu/documents/assessment-report/amversio-epar-public-assessment-report_en.pdf
h1583,https://www.ema.europa.eu/documents/assessment-report/sugammadex-mylan-epar-public-assessment-report_en.pdf
h1631,https://www.ema.europa.eu/documents/assessment-report/breyanzi-epar-public-assessment-report_en.pdf
h1623,https://www.ema.europa.eu/documents/assessment-report/saphnelo-epar-public-assessment-report_en.pdf
h1632,https://www.ema.europa.eu/documents/assessment-report/stimufend-epar-public-assessment-report_en.pdf
h1621,https://www.ema.europa.eu/documents/assessment-report/okedi-epar-public-assessment-report_en.pdf
h1604,https://www.ema.europa.eu/documents/assessment-report/riltrava-aerosphere-epar-public-assessment-report_en.pdf
h1444,https://www.ema.europa.eu/documents/assessment-report/zabdeno-epar-public-assessment-report_en.pdf
h1642,https://www.ema.europa.eu/documents/assessment-report/orgovyx-epar-public-assessment-report_en.pdf
h1521,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-krka-dd-epar-public-assessment-report_en.pdf
h1641,https://www.ema.europa.eu/documents/assessment-report/prehevbri-epar-public-assessment-report_en.pdf
h1571,https://www.ema.europa.eu/documents/assessment-report/abiraterone-mylan-epar-public-assessment-report_en.pdf
h1573,https://www.ema.europa.eu/documents/assessment-report/fingolimod-mylan-epar-public-assessment-report_en.pdf
h1643,https://www.ema.europa.eu/documents/assessment-report/kapruvia-epar-public-assessment-report_en.pdf
h1570,https://www.ema.europa.eu/documents/assessment-report/minjuvi-epar-public-assessment-report_en.pdf
h1618,https://www.ema.europa.eu/documents/assessment-report/nuvaxovid-epar-public-assessment-report_en.pdf
h1611,https://www.ema.europa.eu/documents/assessment-report/vildagliptin/metformin-hydrochloride-accord-epar-public-assessment-report_en.pdf
h1507,https://www.ema.europa.eu/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
h1669,https://www.ema.europa.eu/documents/assessment-report/pepaxti-epar-public-assessment-report_en.pdf
h1652,https://www.ema.europa.eu/documents/assessment-report/filsuvez-epar-public-assessment-report_en.pdf
h1658,https://www.ema.europa.eu/documents/assessment-report/ganirelix-gedeon-richter-epar-public-assessment-report_en.pdf
h1582,https://www.ema.europa.eu/documents/assessment-report/artesunate-amivas-epar-public-assessment-report_en.pdf
h1564,https://www.ema.europa.eu/documents/assessment-report/imcivree-epar-public-assessment-report_en.pdf
h1336,https://www.ema.europa.eu/documents/assessment-report/buvidal-epar-public-assessment-report_en.pdf
h1629,https://www.ema.europa.eu/documents/assessment-report/zolsketil-pegylated-liposomal-epar-public-assessment-report_en.pdf
h1653,https://www.ema.europa.eu/documents/assessment-report/upstaza-epar-public-assessment-report_en.pdf
h1453,https://www.ema.europa.eu/documents/assessment-report/paliperidone-janssen-cilag-international-epar-public-assessment-report_en.pdf
h1592,https://www.ema.europa.eu/documents/assessment-report/trodelvy-epar-public-assessment-report_en.pdf
h1651,https://www.ema.europa.eu/documents/assessment-report/evusheld-epar-public-assessment-report_en.pdf
h437,https://www.ema.europa.eu/documents/assessment-report/ivemend-epar-public-assessment-report_en.pdf
h1620,https://www.ema.europa.eu/documents/assessment-report/sapropterin-dipharma-epar-public-assessment-report_en.pdf
h1575,https://www.ema.europa.eu/documents/assessment-report/bimzelx-epar-public-assessment-report_en.pdf
h1619,https://www.ema.europa.eu/documents/assessment-report/sitagliptin/metformin-hydrochloride-mylan-epar-public-assessment-report_en.pdf
h1595,https://www.ema.europa.eu/documents/assessment-report/aspaveli-epar-public-assessment-report_en.pdf
h1646,https://www.ema.europa.eu/documents/assessment-report/amifampridine-serb-epar-public-assessment-report_en.pdf
h1544,https://www.ema.europa.eu/documents/assessment-report/orladeyo-epar-public-assessment-report_en.pdf
h568,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-mylan-pharma-epar-public-assessment-report_en.pdf
h559,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-mylan-epar-public-assessment-report_en.pdf
h1630,https://www.ema.europa.eu/documents/assessment-report/kimmtrak-epar-public-assessment-report_en.pdf
h1525,https://www.ema.europa.eu/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf
h1657,https://www.ema.europa.eu/documents/assessment-report/kinpeygo-epar-public-assessment-report_en.pdf
h1565,https://www.ema.europa.eu/documents/assessment-report/ryeqo-epar-public-assessment-report_en.pdf
h1625,https://www.ema.europa.eu/documents/assessment-report/paxlovid-epar-public-assessment-report_en.pdf
h1560,https://www.ema.europa.eu/documents/assessment-report/celsunax-epar-public-assessment-report_en.pdf
h1628,https://www.ema.europa.eu/documents/assessment-report/sondelbay-epar-public-assessment-report_en.pdf
h1559,https://www.ema.europa.eu/documents/assessment-report/enspryng-epar-public-assessment-report_en.pdf
h1659,https://www.ema.europa.eu/documents/assessment-report/xenpozyme-epar-public-assessment-report_en.pdf
h1660,https://www.ema.europa.eu/documents/assessment-report/zokinvy-epar-public-assessment-report_en.pdf
h1529,https://www.ema.europa.eu/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
h1562,https://www.ema.europa.eu/documents/assessment-report/xevudy-epar-public-assessment-report_en.pdf
h1350,https://www.ema.europa.eu/documents/assessment-report/vantobra-previously-tobramycin-pari-epar-public-assessment-report_en.pdf
h1585,https://www.ema.europa.eu/documents/assessment-report/vumerity-epar-public-assessment-report_en.pdf
h1648,https://www.ema.europa.eu/documents/assessment-report/carvykti-epar-public-assessment-report_en.pdf
h1586,https://www.ema.europa.eu/documents/assessment-report/voraxaze-epar-public-assessment-report_en.pdf
h1649,https://www.ema.europa.eu/documents/assessment-report/lunsumio-epar-public-assessment-report_en.pdf
h1035,https://www.ema.europa.eu/documents/assessment-report/obizur-epar-public-assessment-report_en.pdf
h1566,https://www.ema.europa.eu/documents/assessment-report/bylvay-epar-public-assessment-report_en.pdf
h1567,https://www.ema.europa.eu/documents/assessment-report/icatibant-accord-epar-public-assessment-report_en.pdf
h1647,https://www.ema.europa.eu/documents/assessment-report/camcevi-epar-public-assessment-report_en.pdf
h1506,https://www.ema.europa.eu/documents/assessment-report/kixelle-epar-public-assessment-report_en.pdf
h1579,https://www.ema.europa.eu/documents/assessment-report/nexviadyme-epar-public-assessment-report_en.pdf
h1671,https://www.ema.europa.eu/documents/assessment-report/sunlenca-epar-public-assessment-report_en.pdf
h1549,https://www.ema.europa.eu/documents/assessment-report/efmody-epar-public-assessment-report_en.pdf
h1578,https://www.ema.europa.eu/documents/assessment-report/ontilyv-epar-public-assessment-report_en.pdf
h1661,https://www.ema.europa.eu/documents/assessment-report/sitagliptin/metformin-hydrochloride-accord-epar-public-assessment-report_en.pdf
h1655,https://www.ema.europa.eu/documents/assessment-report/pirfenidone-aet-epar-public-assessment-report_en.pdf
h435,https://www.ema.europa.eu/documents/assessment-report/tesavel-epar-public-assessment-report_en.pdf
